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REGULATION AND FUNCTION OF MATRIX METALLOPROTEINASE-1 IN 
GLIOBLASTOMA MULTIFORME 
 
By Monika Anand, M.Sc 
 
A thesis submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University 
 
 
Virginia Commonwealth University, 2010 
 
Major advisor: Dr Helen L Fillmore 
Assocaite Professor, Department of Neurosurgery 
 
 
 
Glioblastoma Multiforme (GBM) is an aggressive and fatal cancer of the brain.  It is 
characterized with augmented morbidity and elusion to therapies due in part to the 
incessant infiltration and spread of tumor cells in normal brain.  We investigated the 
function of Matrix metalloproteinase-1, an important enzyme noted to be responsible for 
invasion in other cancers, in GBM and its regulation by epidermal growth factor receptor 
xviii 
 
(EGFR) signaling.  Previous studies from our laboratory demonstrated elevated levels of 
MMP-1 in GBM.  Further studies indicated the involvement of MMP-1 in GBM 
invasion.  
 
 The GBM cell lines T98G, U251MG and U87MG were used for this study.  In 
T98G cell lines, inhibition of MMP-1 by siRNA significantly suppressed basal in vitro 
invasion without impacting cell viability.  The over-expression of MMP-1 was 
accomplished in U251MG and U87MG using the mammalian expression vector, pIRES, 
encoding full length MMP-1 cDNA.  The MMP-1 over-expressing U251MG and 
U87MG cells exhibited significantly enhanced invasion in vitro with no modification in 
the cell proliferation rates.  
 
 A majority of GBM patients present defective EGFR signaling due to over-
expression, amplification or mutation in the receptor.  MMP-1 is known to be up-
regulated by various stimulatory agents including growth factors.  We examined the 
regulation of MMP-1 by EGFR activation and observed the induction of MMP-1 after 
EGF treatment.  Inhibition of the receptor by pharmaceutic inhibitor treatment and 
genetic approaches led to reduction in MMP-1 levels.  We also observed that this 
regulation is primarily mediated by the downstream MAPK pathway.  Inhibition of 
MAPK and not PI3K pathway resulted in diminished MMP-1 protein levels even in the 
presence of EGF.   
 
xix 
 
These studies demonstrate the importance of the EGFR-MAPK signaling pathway 
in the induction of MMP-1 in glioma cell lines.  In addition, MMP-1 plays a role in 
glioma cell invasion in vitro.  These results along with the reports of MMP-1 over-
expression in GBM warrant future studies examining the function of MMP-1 in vivo.   
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CHAPTER 1 
 
 
 
GENERAL INTRODUCTION 
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1.1 Brain Tumors – Overview  
 Brain tissue is composed of two broad classes of cell types-neurons and 
glial cells. Although, neurons are considered to be the primary functional 
components of brain due to the generation and transmission of electrical impulses, 
a large portion of the brain is constituted by glial cells.  These cells are of 
different types; astrocytes, oligodendrocytes, Schwann cells, ependymal cells and 
microglia.  Glial cells provide physical support and nutrition to the neuronal cells 
(Jessen and Mirsky., 2005; Campbell and Gotz., 2002).  A majority of primary 
brain tumors arise from glial cells (astrocytes, oligodendrocytes and ependymal) 
and are collectively regarded as glioma (Louis et al., 2007; Kleihues and Cavenee, 
2000).  Primary malignant CNS tumors account for approximately 2% of all 
cancers (Buckner et al., 2007).  They are the leading cause of death in children 
and the third leading cause of cancer related death in adolescents and adults (15-
34 years of age) (Jemal et al., 2009).  The overall incidence rate of all primary 
brain and CNS tumors in the year 2004-2006 was 18.71 per 100,000 person-years 
with a propensity of slightly increased occurrence in females.  The majority of 
brain tumors occur in the frontal, temporal, parietal and occipital lobes (CBTRUS 
2009 Statistical report). 
 
The occurrence of high grade malignant glioma is ascribable to certain 
genetic abnormalities and possibly environmental factors (Bello et al., 1994).  
Mutations in the type 1 neurofibromatosis gene (NF1), adenomatous polyposis 
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coli (APC) gene, Patched-1 (PTCH-1) gene and the tumor suppressor p53 (TP53) 
gene lead to genetic syndromes that pose a significant risk factor in the 
development of brain tumors.  In addition to these germline mutations, high-dose 
ionizing radiation is a sole environmental factor that is proven to be conducive to 
formation of this neoplasm.  Ionizing radiation treatment is given to patients 
suffering from acute lymphocytic leukemia (ALL) or non-Hodgkin lymphoma 
that predisposes them to increased risk of brain tumors especially gliomas 
(Buckner et al., 2007).  Other environmental risk factors such as use of 
cellphones, head trauma, electromagnetic fields, N-nitroso compounds and 
occupational hazards have also been studied but with inconclusive results 
(Wrensch et al., 2002).  
 
 
1.2 Classification 
In the nineteenth century, prior to the beginning of the brain tumor 
classification system (1920s), all tumors originating in the brain were regarded as 
gliomas (reviewed by Ferguson et al., 2005).  In 1867, Virchow stated that these 
tumors arise from interstitial brain tissue.  In 1875, Golgi showed that some brain 
tumors are composed of star-shaped neuroglial cells.  An extensive, thorough and 
organized work on the classification of brain tumors was started by Bailey and 
Cushing in 1922 (Bailey and Cushing, 1926).  Thereafter, the World Health 
Organization (WHO) proposed a new comprehensive classification of neoplasms 
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affecting the CNS based on the cell-origin in 1993.  As per the latest WHO 
classification (2007), gliomas belong to the neuroepithelial tumors of the CNS, 
arising from glial cells.  Gliomas include astrocytoma, glioblastoma, 
oligodendroglioma, ependymoma and other neuroepithelial tumors.  The 
incidence rate for neuroepithelial tumors is 1.4 times higher in males than in 
females (CBTRUS, 2009)  
 
In addition to laying out a classification for brain tumors, WHO has also 
defined a grading system for gliomas that is based on certain histological markers; 
increased cellularity, cell proliferation, angiogenesis, necrosis and mitosis.  The 
tumor grades increase with progressive cell proliferation and necrosis.  Grade I is 
a low grade brain tumor, regarded as astrocytoma and it is well circumscribed, 
therefore considered relatively benign, affecting children and young adults.  
Eighty percent of patients with Grade I tumors survive greater than 20 years.  
Grade II is a low grade diffuse astrocytoma that grows slowly but has an inherent 
tendency to invade normal brain tissues and eventually progress to Grade III and 
IV.  The median survival rate is highly variable; between five to ten years. Grade 
III (Anaplastic astrocytoma) demonstrates histological evidence of malignancy, 
including nuclear atypia and accelerated mitotic activity.  Grade IV (Glioblastoma 
Multiforme, GBM) tumors are malignant, characterized with hyper-cellularity, 
profound vascular highly active at mitotic level, necrotic with extremely poor 
prognosis and fatal outcome (Louis et al., 2007).  Overall, gliomas account for 
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33% of all tumors, of which glioblastomas are the most common, contributing 
54% [Figure 1.1].  
 
 
 
 
Figure 1.1 A major portion of primary brain and CNS tumors is 
comprised of non-malignant meningioma (~34%) followed by glioblastoma 
(~17%).  Gliomas are tumors arising from glial cells and include astrocytoma, 
glioblastoma, oligodendroglioma, ependymoma, mixed glioma, malignant glioma 
NOS (not otherwise specified) and other rare types (CBTRUS, 2010).  This figure 
shows the distribution of these various subtypes of gliomas (N=50,240).  GBMs 
are predominantly represented in glioma (53.4%).  The astrocytoma and 
oligodendroglioma together constitute 29% followed by small percentages of 
ependymomas and mixed gliomas.  (CBTRUS Statistical Report, 2010, NPCR 
and SEER data from 2004-2006)  NPCR= National Program of Cancer Registries.  
SEER=Surveillance, Epidemiology and End Results. 
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The incidence of glioma is higher in males (7.06 per 100,000 person 
years) as compared to females (4.96 per 100,000 person years). 
 
 
1.3 Symptoms and Diagnosis 
General symptoms associated with brain tumors may include headache, 
memory loss, cognitive impairment, seizures, visual, speech and sensory deficits, 
nausea and vomiting (Chang et al., 2005).  Headaches tend to vary in intensity 
and are more frequent and severe in the morning.  Seizures are presenting 
symptoms in patients with supratentorial tumors.  Depending on the location of 
the tumor, the signs and symptoms vary.  For example, in patients with tumors 
located in the parietal lobe, speech dysfunction and sensory loss are observed.  
Vision dysfunction may be the outcome of tumors in parietal or occipital lobe.  
Temporal lobe tumors are characterized by memory loss and behavioral changes.  
A tumor in the frontal lobe could lead to imbalance, speech deficits, seizures 
and/or dementia.  Lack of muscle coordination is observed in patients with 
cerebellar tumors (Newton, 1994).  Thus, a person presented with persistent 
headache with nausea, vomiting or seizures is normally evaluated for the presence 
of a tumor mass in brain. 
 
Currently, a variety of imaging methods are being used to assess tumor 
mass, extent, localization and malignancy level. Computer tomography (CT) scan 
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and magnetic resonance imaging (MRI) technology reveal most of the anatomical 
information such as the size and location of the tumor.  MRI also gives us 
information on mass effect, edema, necrosis and hemorrhage at high tissue 
contrast.  Although, both CT and MRI images are of high spatial resolution, it is 
the MRI that delivers better resolution.  MRI gives us a sequence of different sets 
of images of a brain tumor, each using a particular parameter- T1-, T2-, proton-, 
perfusion-weighted images.  On a T2-weighted scan, water and fluid-containing 
tissue is bright and thus, edema can be seen on a T2-weighted scan as a bright 
region.  An improvisation on T2-wighted scan is FLAIR (fluid attenuated 
inversion recovery) that separates water (dark) from edematous tissue (bright).  
Most brain tumors are hypotense on T1-weighted images and hypertense on T2-
weighted, FLAIR images.  In GBM, the blood brain barrier (BBB) is disrupted 
leading to the leakage of the contrasting media [such as gadolinium (Gd)] that can 
be seen as a contrast enhanced region.  Thus, MRI with gadolinium is considered 
to be the better diagnostic tool for confirming a diagnosis (Jacobs et al., 2005).  
 
There have been additions and improvisations in MRI technology that help 
a surgeon tremendously.  Dynamic contrast-enhanced MRI assesses the vascular 
hyperpermeability of tumor vessels thereby helping a surgeon make predictions 
for tumor grade.  Magnetic resonance spectroscopy (MRS) and positron emission 
tomography (PET) are other important tools that are being used to examine the 
molecular and metabolic tumor markers in heterogeneous tumors such as GBMs.  
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The imaging is followed by histopathological examination of tumor samples taken 
from the patient. Confirmation of tumor grade is made only after histological 
analysis of the tumor specimens is complete. 
 
Glioblastoma Multiforme is the most aggressive and invasive tumor of all 
the CNS tumors and constitutes approximately half of the gliomas.  The hallmarks 
of GBM that set them diagnostically apart from low grade gliomas are increase 
cellular proliferation, angiogenesis and pseudopallisading necrosis (Kleihues and 
Cavenee, 2000).  Moreover, the invasive nature of this tumor renders surgical 
resection as a merely palliative treatment.  Inevitably, the tumors recur due to the 
infiltration of tumor cells in a diffused manner to normal tissue. These recurring 
tumors are also highly resistant to therapies. 
 
The average age of GBM diagnosis is approximately 55 years. The 
diagnosis is made using MRI scans (using gadolinium) of patients with GBM that 
show a ring-enhanced mass lesion with low signal intensity at the center. 
Thereafter, biopsy is conducted that confirms increased necrosis in the center and 
augmented vascularity in the ring-enhanced region.  The surrounding region is 
composed of normal brain parenchyma that is being diffused with infiltrative 
tumor cells. 
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GBMs are categorized into either primary (de novo) or secondary glioma.  
In a general population, approximately 90% of the patients are presented with de-
novo GBMs (Ohgaki and Kleihues, 2007).  Primary glioblastomas are typically 
diagnosed at a terminal stage without any presence of a previous clinical or 
histopathological evidence of pre-existing less malignant lesion.  The average age 
of patients with de-novo GBM is 62 years.  Secondary glioblastomas develop 
gradually from a low grade diffused astrocytomas (Grade II) or Grade III 
anaplastic astrocytoma and are diagnosed in younger people (average age 45 
years). These factors notwithstanding, the clinical outcome of a patient with GBM 
does not differ between primary or secondary GBMs.  However, there are distinct 
molecular and genetic pathways in the development of primary and secondary 
GBM (Ohgaki and Kleihues, 2007).  These pathways may have some impact on 
patient‟s outcome and response to therapy.  Thus, studying these molecular events 
that lead to the genesis of GBM may help predict the outcome of a patient.  
 
 
1.4 Treatment  
 1.4.1 Surgery 
GBM poses greatest challenges to a physician due to its highly aggressive 
invasive pattern and resistance to therapies.  Factors such as neurotoxicity after 
therapy, edema due to tumor capillary leakage resulting in intracranial 
hypertension and drug delivery complications due to blood-brain barrier make this 
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tumor highly difficult to treat.  Surgery, radio- and/or chemotherapy are the 
mainstay treatment options in GBM.  Grade I tumors are largely treated with 
surgical resection only whereas the treatment options in low grade astrocytoma 
vary from patient to patient.  The clinical prognosis for Grade III and IV tumors is 
extremely poor, with Grade III anaplastic astrocytoma having median survival of 
two to three years and Grade IV GBM, a dismal ten to twelve months ( Davis et 
al., 1999).   
 
At the initial stages of treatment after GBM diagnosis, resection of the 
tumor by surgery is carried out based on the tumor location and its extent.  
However, the aggressive infiltration of the GBM tumor cells makes complete 
surgical resection of the tumor unachievable.  In any case, surgical debulking of 
the tumor is vital for relieving intracranial pressure due to tumor mass and 
improving survival (Hentschel et al., 2003).  Thus, surgery largely remains an 
important palliative procedure.  It is important to note that complete resection is 
defined as the absence of contrast- enhancing tumor image seen on a 
postoperative MRI.  Conclusions from a recent phase III control trial reveal that 
complete surgical resection could be obtained by performing fluorescence-guided 
resections with 5-aminolevulinic acid (ALA) – induced tumor fluorescence as 
compared to the conventional microsurgery (Stummer et al., 2006).  
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1.4.2 Radiotherapy 
 After surgical resection, the patients are analyzed for their general health.  
A conclusive plan and individual regimen of radio- and chemotherapy is decided 
upon.  A better prognosis is obtained if a patient is young, has a high Karnofsky 
Performance Status (KPS), a high score on Folstein test and has promoter 
methylation of the O6 methylguanine methyltransferase (MGMT) gene.  KPS is a 
scale that runs between zero (death) to 100 (disease-free state) and is based on 
parameters such as ability to take care of oneself, requirement of medical care, 
progression to disease etc.  The Folstein test is a questionnaire that assesses a 
patient‟s performance in arithmetic, memory and orientation.  MGMT is a repair 
enzyme that is involved in the GBM pathology.  Methylation of the promoter 
region of MGMT inhibits the enzyme and improves prognosis in some patients 
(Krex et al., 2007; Esteller et al., 2000; Hegi et al., 2004).  Radiation treatment 
has been consistently used as part of adjuvant therapy after it was established that 
it increased the median survival time from 4 months to 10 months (Walker et al., 
1979).  Varying doses, fractions and time interval between the fractional doses of 
radiation have been examined for best efficacy.  The aggressive growth pattern in 
GBM along with the lack of sufficient blood supply makes the tumor environment 
largely hypoxic and necrotic.  These conditions make the tumor highly resistant to 
radiation therapy (Mehta et al., 2004).  To circumvent this issue, many radio- 
sensitizers have been tried, including misonidazole and metronidazole, without 
any positive results (Mehta et al., 2004). 
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  Radiation treatment can be given externally (external beam radiation) or 
internally (brachytherapy).  Brachytherapy involves placement of radioactive 
sources inside the body at or near the resection site.  Patients with GBM are 
generally treated with external beam radiation; conventional and/or stereotactic.  
In conventional external beam radiation treatment, a single beam of radiation is 
delivered to the patient in multiple directions to target the tumor volume from all 
the sides.  Radiation toxicity to nearby healthy tissues is a disadvantage to this 
procedure.  Stereotactic radiation treatment involves delivering a high dose of 
radiation directly to the tumor/resected area in a single or two to three sessions.  
This type of radiation treatment minimizes the death of healthy tissue, requires 
lesser time, is equally or more effective but it is suitable to only small, well 
defined tumor masses (Buckner et al., 2007).  The standard external beam 
radiation treatment consists of 25-35 daily treatments for over five to seven weeks 
for a total radiation dose of 60 Gys (Chandana et al., 2008).  In patients above 70 
years of age, a total of 50 Gys with 1.8 Gy fractions has been found to improve 
survival outcome (Keime-Guibert et al., 2007).  
 
 
1.4.3 Chemotherapy 
Studies in finding appropriate drugs for brain tumors have been ongoing 
for the past 30 years with very limited breakthroughs.  Carmustine (BCNU) 
chemically 1, 3-bis (2-chloroethyl)-a-nitrosourea, was the first single drug used in 
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the treatment of malignant glioma in early 1970s (Barker et al., 1973; Wilson et 
al., 1976).  In majority of patients, BCNU used to be given to patients 
intravenously but nausea and vomiting were experienced by patients within 2 
hours of infusion.  An improvised version of BCNU delivery method, Gliadel 
wafers, was developed (Wu et al., 1994).  These small wafers coated with BCNU 
were placed directly to the site of tumor.  However, this method too has its own 
complications.  There was risk of toxicity to adjoining healthy tissues and 
decrease in blood count making the patient susceptible to infection and bleeding.  
Moreover, it was costly for most of the patients.  Concurrently procarbazine was 
also developed and has been used in the clinical trials (Kumar et al., 1974).  Over 
a period of time, due to dismal improvement in survival, multidrug treatments 
were initiated.  The drug combination procarbazine, CCNU (lomustine) and 
vincristine (PCV) was found to be highly effective (Gutin et al., 1975). However, 
this therapy was accompanied with extremely severe side effects.  Advent of 
Temozolomide (TMZ) (Figure 2) was a breakthrough in the chemotherapeutic 
treatment of GBM patients.  TMZ (Temodar; Schering-Plough, Kelinworth, NJ) is 
an alkylating agent that induces methyl-groups at N-7 or O-6 positions of the 
guanine residues in DNA.  Due to the damage to DNA, there is considerable cell 
death and tumor growth control.  TMZ is very stable at acidic pH but its 
degradation increases between neutral to basic pH.  The drug is administered in its 
pro-form and during physiological pH, it rapidly degrades and becomes activated. 
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Figure 1.2. Chemical structure of Temozolomide  
 
 
 
Upon hydrolysis in the physiological pH, the TMZ ring structure collapses 
releasing N2 from (N at positions 2 and 3), CO2 gas (C-4), 5-aminoimidazole-4-
carboxamide (AIC) (N-1 and imidazole atoms), a natural component of urine, as 
by-products.  The methyl group transfer takes place immediately after reaction 
with water/hydroxyl group.  
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Although there is considerable cell death due to TMZ, tumor cells may 
develop resistant mechanisms to it by expressing repair enzymes such as the 
above mentioned O6-methylguanine-DNA methyltransferase (MGMT) gene.  
TMZ induced methyguanine adducts are removed by MGMT as part of repair 
process.  This MGMT-mediated resistance to TMZ is overcome by pre-treatment 
with O6-benzylguanine; a substrate analog for MGMT.  TMZ itself is also used as 
a pretreatment to deplete the levels of MGMT in tumor cell population (Tolcher et 
al., 2003). 
 
Clinical trials using TMZ have shown that it can be regarded as an oral 
single-agent drug superior to other drugs for recurrent GBM patients (Yung et al., 
2000).  Recently, the European Organization for Research and Treatment of 
Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) performed 
a randomized, multicenter, phase III trial to compare radiotherapy with TMZ as 
adjuvant followed by TMZ treatment for six months and radiotherapy alone.  The 
patients with TMZ plus radiotherapy had a higher 2-year survival rate and 
increased progression-free survival as compared to the radiotherapy alone (Stupp 
et al., 2005).  Such studies have made TMZ administration and fractionated 
radiotherapy following near complete surgical resection of tumor as the standard 
care in the treatment of GBM patients today. 
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Despite latest revolutionary surgical tools, newer and better methods of 
drug delivery, the disease is incurable and has very high morbidity rate.  New 
insights into the glioma molecular biology may provide hope.  As stated earlier, 
GBM is a heterogenous tumor with dysregulation of multiple signaling pathways 
due to genetic mutations.  Using glioma biology as basis, new chemotherapies are 
underway.  Most of these therapies target molecules that are involved in growth-
factor mediated cell-signaling pathways that lead to increased cell proliferation 
and neo-angiogenesis.  
 
 
1.5 Glioma Biology  
As mentioned above, GBMs either develop de-novo, without any previous 
manifestation of the disease or they progress from low-grade astrocytomas.  The 
important genetic alterations that lead to GBMs are listed in Table 1.  GBMs are 
characterized by loss of heterozygosity (LOH) at chromosome 10q, epidermal 
growth factor receptor (EGFR) amplification, mutation or over-expression, 
p16
INK4a
 deletion and loss or mutation in phosphatase and tensin homolog 
(PTEN).  During development into secondary glioblastomas from low grade 
astrocytomas, the most characterized genetic alteration is mutation in TP53.  This 
is followed by accumulation of other additional genetic mutations such as 
alterations in retinoblastoma protein (RB) gene, PDGF and PDGF-α over-
expression, LOH at chromosome 19q and 10q and PTEN mutations.  The primary 
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and secondary GBM also differ in the promoter methylation patterns and RNA 
expression profiles (Ohgaki and Kleihues, 2007).  In addition, the DNA repair 
mechanisms that go awry in GBM include nucleotide excision, base excision and 
mismatch repair mechanisms.  As mentioned earlier, MGMT is a mismatch-repair 
enzyme that helps in protecting a cell from alkylating agents generated by 
environmental damage.  In addition, MGMT also imparts cancer cells a resistance 
mechanism to chemotherapeutic drugs that induce cell death by acting as DNA-
alkylating agents.  In a subset of GBM patients, MGMT gene is hyper-
methylated.  In these patients, treatment with DNA-alkylating drug has better 
prognosis (Nagarajan and Costello, 2009). 
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Table 1- Genetic Events in GBMs 
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 Aberrant RTK (receptor tyrosine kinase) (EGFR, PDGFR, MET) signaling 
together with hyperactivated downstream pathways including RAS/MAPK, 
PI3K/AKT/mTOR, Protein kinase C (PKC) signaling, depletion of p53 and 
defects in RB pathway contribute significantly to glioma growth, proliferation, 
survival, vascularization and invasion in GBMs (Grzmil and Hemmings, 2010) 
(Figure 3).  Amplification and over-expression of EGFR is more common in 
primary GBMs than secondary GBMs.  EGFR amplicons are often mutated, with 
EGFRvIII mutation (deletion of exon two to seven), as the most prevalent form.  
The EGFRvIII variant is a constitutively active form of the receptor.  This type of 
mutation has profound effects on cell proliferation, migration and vascularization.  
In addition, this truncated receptor also confers resistance to chemotherapeutic 
agent, cisplatin by modulation of BcL-xL and caspases in cell death pathways 
(Nagane et al., 1998).  
 
 In a vast majority of malignant brain tumors, including GBM, mutations in 
the TP53 pathway and/or retinoblastoma (RB1) pathway are also prevalent.  TP53 
mutations are the hallmark event in secondary GBMs.  They also occur in primary 
form of GBM, although at a lower frequency (<30% of the cases, Ohgaki et al., 
2004).  Mutation pattern involving G: C → A: T, frequently at two hotspot codons 
248 and 273 in TP53 gene, are directly associated with progression to secondary 
GBMs.  In GBMs, where TP53 mutation is absent, there is an amplification of 
MDM2 (murine double minute) that rapidly degrades TP53 protein (Biernat et al., 
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1997).  TP53 protein gets activated after DNA damage in response to radiation or 
chemical mutagens.  MDM2 binds to TP53 facilitating its degradation by 
ubiquitinization.  Conversely, MDM2 gene is up-regulated by TP53.  In normal 
cells, this regulatory feedback loop is maintained but in a transformed cell, this 
regulation is dysfunctional.  Another gene product, p14
ARF
 binds to MDM2 and 
prevents MDM2 –mediated degradation of TP53.  Thus, loss of TP53 function, in 
a tumor cell, may result from aberrant expression in MDM2 and p14
ARF
 gene.  
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Figure 1.3 Major pathways in gliomagenesis Schematic representation of 
EGFR signaling in glioma.  Epidermal growth factor binds to its receptor EGFR 
leading to receptor dimerization and autophosphorylation at various tyrosine (Y) 
residues.  This further results in activation of several downstream signaling 
pathways among them ras-raf-MAPK, PI3K/AKT and JAK/STAT are prominent.  
MAPK activation affects DNA synthesis and cell proliferation and PI3K/AKT has 
role in cell survival. 
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 RB1 (retinoblastoma 1) pathway is equally dysregulated in both primary 
and secondary GBMs.  RB1 protein is phosphorylated by the CDK4/cyclin D1 
complex releasing E2F transcription factor which induces genes that aid in G1→S 
transition in the cell cycle.  Another important protein, p16
INK4a
 binds to CDK4 
and inhibits RB1 phophorylation, thus inhibiting the G1→S transition. 
 
 Loss of heterozygosity (LOH) at chromosome 10q is a major genetic 
alteration that occurs in 60-80% population with GBMs (Fujisawa et al., 2000, 
Rasheed et al., 1995).  As an exclusive event, complete loss of chromosome 10 
may be seen only in primary GBMs.  The commonly deleted loci at chromosome 
10 are 10p14-p15, 10q23-24 (PTEN) and 10q25-qter that encodes several tumor 
suppressor genes.   
 
 Promoter methylations of the p14
ARF
, p16
INK4a
,
 
RB1, MGMT and tissue 
inhibitor of metalloproteinase-3 (TIMP-3) genes are common events in secondary 
GBMs (Nagarajan and Costello, 2009).   In a cDNA expression profile study 
conducted to assess differences in gene expression, IGFBP2 gene was 
significantly over-expressed in primary GBM (Godard et al., 2003).  Microarray 
analysis with subsequent gene annotation revealed alterations in genes involved in 
cell cycle regulatory pathways in secondary GBM and loss of function in genes 
involved in signaling pathways in primary GBMs (Tso et al., 2006).  EGFR, 
MDM2 and MMP-9 genes were elevated in primary GBM as observed from both 
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arrays and immunohistochemistry profiles (Watanabe et al., 1996; Tso et al., 
2006; Biernat et al., 1997). 
 
 
1.5.1 Glioma Biology as basis for developing novel drug targets 
 GBM treatment remains unfruitful due to numerous factors that include 
lack of effectiveness and high cytotoxicity of the drugs, aggressiveness of the 
disease and inability for complete surgical resection of the tumor.  These pitfalls 
in the therapy have led to the development of novel drugs that target cellular 
signaling pathways in gliomagenesis.  GBM is a heterogeneous tumor wherein 
multiple signaling pathways are dysregulated.  Targeting different molecules 
simultaneously is important for a successful outcome. In tumor cells, several 
diverse signaling pathways are constitutively active.  Some of these pathways 
converge to common downstream transcriptional factors.  Developing a drug 
against a target upstream in a signaling pathway would not be as beneficial as 
developing multiple downstream targets because inhibition of upstream molecules 
in a signaling pathway may result in other compensatory mechanisms leading to 
drug resistance.   
 
 Some of the small molecule inhibitors that seem promising are inhibitors 
that target EGFR (erlotinib), Akt (perifosine), farnesyl transferase (lonafarnib), 
Met (XL184), mTOR (sirolimus), PI3K (BEZ235), PDGFR (imatinib) and TGF-β 
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(AP12009).  A complete comprehensive list of inhibitors to such oncogenic 
molecules is given in Table 2 (Adamson et al., 2009).  The anti-angiogenesis 
approach has been significant with regards to GBM because aggressive growth of 
the tumor leads to hypoxic conditions that in turn cause neovascularization.  
Recently the developed anti-angiogenic drug, Bevacizumab, a monoclonal 
antibody against vascular epidermal growth factor (VEGF) has been FDA 
approved in 2008 for use in breast cancer patients.  This drug is a strong candidate 
for GBM patients and is under clinical trials for GBM therapy (Adamson et al., 
2009).  Other anti-angiogenic drugs under clinical trials for GBM are the ones that 
target αvβ5 integrins (cilengitide), hepatocyte growth factor (HGF) (AMG-102) 
and VEGFR (sunitinib) (Adamson et al., 2009). 
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Table 2 Current active clinical trials for GBM in United States (Adamson et 
al., 2009, www.clinicaltrials.gov).  The most common chemotherapies under 
investigation include small-molecule targeted therapies (directed against 
molecules in signaling pathways), anti-angiogenic therapies, immunotherapies 
and gene therapies.  The drugs listed here are primarily against the molecues 
aberrantly activated or over-expressed. 
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Immunotherapy 
In addition to above therapies, another promising approach is using 
immunotherapy where patients own immune system is used to target the tumor 
cells (Kanaly et al., 2010). Injections of tumor peptides by RNA, DNA, Viral 
particles or whole cells leads to sensitization of these lymphocytes against a tumor 
antigen leading to specific clearance of tumor cells without affecting the normal 
healthy tissue.  For example, TP-38 is a genetically engineered protein that has 
the EGFR ligand (TGF-α) fused with pseudomonas exotoxin.  The N-terminus of 
TGF-α protein binds with EGFR followed by TP-38 exotoxin cleavage and cell 
death (Rainov and Soling, 2006). 
 
  In the passive approach of immunotherapy, the lymphocytes are removed 
from a patient‟s body, expanding those cells that demonstrate activity against the 
tumor cells and reintroducing them back in the patient. For example, dendritic 
cells (DCs) are loaded with tumor specific peptides (EGFRvIII), tumor lysates, 
tumor stem cell mRNA and injected into the GBM patient as vaccines (Parney et 
al., 2000).  In one such Phase I clinical trial of DC immunotherapy, survival was 
prolonged to 133 weeks as compared to 33 weeks in control patients and the 
therapy was found to be completely safe (Yu et al., 2006).  In a more tumor-
specific target approach, EGFR vIII vaccine has been developed and has delivered 
promising results in two separate clinical trials (Schmittling et al., 2008; Parney et 
al., 2010).  
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Brain Tumor Stem Cells  
During developmental stages, mammalian brain contains a population of 
neural stem cells (NSCs) that have the capacity to self-renew and proliferate.  The 
presence of such NSCs in adult human brain has been reported in separate studies 
(reviewed by McKay 1997; Uchida et al., 2000).  These NSCs gained great 
significance in CNS repair mechanisms post-injury (Laywell and Steindler, 2002).  
Presence of neural progenitor cells in adult brain strongly links normal 
physiological development of brain with brain cancer (Pardal et al., 2003).   
 
Recently, brain tumor stem cells (BTSCs) have been identified and 
isolated from brain tumor specimens from patients by using a neural stem cell 
marker CD133 (Ignatova et al., 2002; Singh et al., 2003, 2004).  These CD133
+
 
BTSCs show high capacity to self-renew and proliferation in-vitro and in-vivo.  
The CD133
+
 tumor neurospheres express stem-cell marker, nestin during neural 
stem cell culture conditions and upon changing culture conditions to serum-
containing media, they differentiate into a mixed population of neurons, 
astrocytes and oligodendrocytes.  More recently, it has been reported that 
isolation of CD133
-
 cells from GBM also form orthotopic tumors in mice and 
give rise to CD133
+
 cells in vivo (Wang et al., 2008).  This suggests that there 
may be other tumor initiating cells in GBM that do not express CD133.   
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Understanding the biology and gene expression profile of BTSCs would 
provide means to test novel therapeutics strategies.  Prominent signaling pathways 
that are vital for survival of BTSCs are PI3K, NOTCH, Wnt, SHH.  These 
pathways are needed to be targeted for elimination of BTSCs from tumors.  
Another approach would be to promote differentiation in BTSCs as it has been 
found that using bone-morphogenic proteins (BMPs)  induced differentiation and 
prolongs survival in mice models (Atkinson et al., 2009, Hadjipanayis et al., 
2009).   
 
 
1.6 Invasion 
 
1.6.1 General overview of Invasion and metastasis in cancers 
other than GBM 
In any cancer setting, tumor cell invasion and metastasis dramatically increase 
the morbidity and mortality due to cancer.  To achieve invasive properties, a 
subpopulation of tumor cells must recognize the ECM molecules present in the 
vicinity of the cell, attach to these molecules by specific receptors present on the 
cells and modify the ECM by cleaving physical barriers paving a way for the 
tumor cell to migrate to other parts of the body (Geho et al., 2005). 
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Figure 1.4: Invasion/Metastasis in cancer 
Invasion process has three basic steps: 
a) The tumor cells detach from the solid tumors at the site of origin. 
b) The cells then adhere to the extra-cellular matrix (ECM) proteins by 
expressing specific receptors that bind to ECM proteins. 
c) The cells release proteases and other molecules that aid in the degradation of 
complex ECM molecules  thereby paving a way for the tumor cell to navigate 
through adjoining normal tissue.  
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Following invasion through ECM and blood vessels, the tumor cells 
migrate and attach to a new location. The new tumor mass is formed by up-
regulating complex molecular machinery that aids in the process of proliferation, 
growth and neo-angiogenesis. These molecular mechanisms are similar to the 
ones that aid in normal physiological growth. During normal development, the 
cellular migration is tightly controlled by organism‟s homeostasis. In contrast, 
during metastasis, there is an unchecked constitutive up-regulation of molecular 
mechanisms that eventually leads to the death of the organism. 
 
At the initial phase of the invasion process, interaction between tumor 
with ECM and stromal cells (Liotta et al., 2001) are mediated by cell-cell, cell-
ECM contact and secretion of soluble factors by tumor cells that interact with 
ECM and stromal cells.  The cell-cell and cell-ECM contacts are made by special 
class of adhesion receptor family of proteins that include selectins, immunoglobin 
cell-adhesion molecules, cadherins and integrins.  The most widely studied cell 
adhesion receptor protein is integrin family of receptors.  Integrins are 
heterodimeric transmembrane proteins that bind to specific ECM molecules at the 
extracellular side and specific cytoskeletal (CSK) adaptor proteins intracellularly 
(Giancotti and Ruoslahti, 1999) such as focal adhesion kinase (FAK) (Guo and 
Giancotti, 2004).  In normal physiology, when a cell is detached from the ECM, it 
does not survive, a  process referred to as “anoikis” (Frisch and Ruoslahti, 1997).  
Tumor cells escape anoikis by activating PI3-kinase/AKT pathway that inhibits 
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caspases (Frisch and Ruoslahti, 1997).  Ligand binding to integrins leads to 
integrin-clustering and recruitment of intracellular signaling components 
following which Rho family of GTPases, MAP and PI3-kinases activate.  
Receptor tyrosine kinases, integrins and G-protein coupled receptors co-ordinate 
and get activated during tumor cell‟s transformation to a migratory and invasive 
phenotype.  Cytoskeletal changes like actin-polymerization and myosin-
contraction are mediated by Rho-kinases and cause polarization of the cell, 
membrane extension and cell substratum attachment in the migration process.  
 
Tissue remodeling by matrix degradation and turnover are important 
events during physiological development.  These events are also an integral part 
of wound healing, tumor necrosis and inflammation.  The most important 
enzymes that are at the forefront of matrix degradation are matrix 
metalloproteinases (MMPs).  Due to the proteolytic activity of MMPs, the rigid 
barriers of ECM are removed, latent forms of growth factors, proteases and 
chemotactic agents are activated and bioactive molecule within ECM are 
generated.  In addition, the integrin binding sites in the ECM become exposed to 
interact with cells for transmitting migratory and survival signals (Davis, 1992).   
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1.6.2 Invasion in Glioblastoma Multiforme (GBM) 
One of the important underlying reasons for the failure of GBM therapies 
is the ability of GBM cells to invade local brain parenchyma.  Maximal surgical 
resection only slightly helps in improving patient‟s outcome as by the time the 
disease is diagnosed; tumor cells may have already infiltrated and cannot be 
identified.  Thus, there is a dire need for therapeutic approaches that target the 
invasion process in GBM (Davis and McCarthy, 2001). 
 
  Brain tumor cells follow the basic steps of invasion with the unique 
exception that they rarely invade outside the brain tissue and metastasis by GBM 
cells is confined to within the brain tissue.  There is no invasion and extravasion 
in and through the vasculature (Burger and Scheithauer, 1994; Hunter et al, 2003; 
Kleihues and Cavenee, 2000).  The invasion pattern followed by primary brain 
tumors is different from the tumors that metastasize to the brain from other parts 
of the body.  Primary brain tumors invade aggressively to wider margins within 
the brain, generally as single cells, some have the tendency to invade along the 
periphery of blood vessel walls or along white matter tracts in Virchow-Robins 
space (Fillmore et al., 1999; Bellail et al., 2004).  These findings suggest that the 
migration of invading cells is dependent on specific substrates present in the 
microenvironment of CNS.  Metastatic tumors that invade to brain generally have 
a well-defined mass and invade as groups of cells.  Thus, a metastatic brain tumor 
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has relatively better response to surgical resection as compared to a primary 
malignant brain tumor.  
 
Various studies have been conducted to study the migration pattern of 
GBM cells (Swanson et al., 2000, 2003; Mandonnet et al., 2003; Harpold et al., 
2007).  These studies are based on in-vitro experimental models (tumor spheroids) 
of tumor invasion and suggest that various patterns of migrations are followed by 
GBM cells including isolated islands, branching and dispersion both near and 
away from the tumor boundary.  These results have been corroborated by a 
mathematical model based on partial differential equations (PDEs) that use 
glioma cell density and concentration of nutrients, proteases such as MMPs and 
ECM (Kim et al., 2009). It was shown that different dispersion patterns arise from 
the differences in haptotactic, chemotactic and cell-cell adhesion factors. The 
chemotactic flux is generated when tumor cells get attracted to glucose for energy 
requirement (Warburg effect) and move in the direction of glucose gradient. The 
model was based on the consideration that brain ECM is a deformable mass of 
fibers that is constitutively being degraded and remodeled by MMPs. Using this 
model, they observed that increasing cell-cell adhesion forces slowed migration 
confirming earlier reports of requirement of loss of cell-cell contacts for invasion 
in T98G cells (Perego et al.,2002). 
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 ECM in brain mainly consists of hyaluronan, proteoglycans, tenascin-C 
and thrombospondin.  Due to low abundance of fibrillar collagen, laminin and 
other molecules that impart strength to the ECM, it is largely amorphous and 
loosely bound and therefore difficult to study (Chintala et al., 1996).  
Proteoglycans such as chondroitin, heparin sulphates and glucosaminoglycans 
(GAGs) are present in brain parenchyma (Chintala et al., 1996).  Other 
proteoglycans present in the brain are hyaluronic acid (HA), tenascin and 
cytotactin (Table 3).   
 
 
 
Table 3: Components of ECM in brain (Adapted from Chintala et al., 1996) 
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The components of ECM continuously change during development and diseased 
states modulating brain cell growth, differentiation and invasion by different 
mechanisms.  Hyaluronic acid (HA) is increased several fold in primary brain 
tumors comparable to the levels present during developmental stages of the brain.  
HA has been regarded to be involved in facilitating the tumor migration and 
invasion using specific cell surface receptors, cluster differentiation 44 (CD44) 
(Akiyama et al., 2001).  Tenascin C is also up-regulated in brain tumors and its 
levels correlate with tumor grade (Higuchi et al., 1993; Zagzag et al., 1995).  The 
expression of type IV collagen and laminin has also been reported to be found in 
the vessel walls along the endothelial glomerulus-like proliferations (Bellon et al., 
1985).  Type V collagen and fibronectin is present in vessel walls in the basement 
membrane and perivascular matrix and type 1 and III collagens are observed in 
the vessel walls and perivascular connective sheet (Bellon et al., 1985). 
 
 
1.7 Matrix Metalloproteinases (MMPs) 
1.7.1 Nomenclature and Classification 
MMPs are a large family of zinc-dependent endopeptidases that 
collectively have the ability to cleave every component of ECM.  The first 
member of the family, MMP-1, also referred to as collagenase-1, was described 
by Gross and Lapiere in 1962 while studying tadpole morphogenesis (Gross and 
Lapiere, 1962).  Since then, 23 members of the MMP family have been found to 
40 
 
be expressed in human.  MMPs play a crucial role in normal physiological 
processes like tissue remodeling during embryonic development (Page-McCaw et 
al., 2007), wound healing (Parks et al., 2004) and cancer (Egeblad and Werb, 
2002).  Historically MMPs have been divided into four categories depending on 
their substrate-specificites: Collagenases, Gelatinases, Stromelysins and 
membrane-type MMPs (MT-MMPs) (Table-4).  Collagenases act on collagens 
type I, II, III, fibrillar collagens type I, II, III, VI, IX and include MMP-1, -8 and -
13.  MMP-18 is also a collagenase found in Xenopus species but it is not 
expressed in humans.  There are two groups within gelatinases- Gelatinase A 
(MMP-2) and Gelatinase-B (MMP-9).  Their primary substrate is gelatin type I, 
II, III but they can also act on collagen type IV, V, VII, X, fibronectin and elastin.  
Stromelysins are also divided further into three subgroups- stromelysin 1, 2 and 3.  
They act on fibronectin, laminin, collagens type II, IV, V, IX, gelatin type I, III, 
IV, V.  Stromyelin 3 (MMP-11) is a unique enzyme that does not cleave ECM 
molecules such as collagen, laminin, elastin and fibronectin.  Most of the 
membrane-type MMPs cleave progelatinase-A.  These membrane-tethered MMPs 
are important for regulating cell behavior as they influence cell-surface and ECM 
activity.  The secreted MMPs also aid in the signaling mechanisms by cleaving 
latent growth factor molecules in the ECM.  In addition, they can also bind to the 
integrins or CD-44 cell surface receptors.  Each member protein is encoded by a 
different gene and most of the genes for MMPs are clustered on chromosome 11 
indicating a common evolutionary origin.  The region Ch11q23, where MMP 
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genes are localized, is found to be amplified in several solid tumors (Rooney et 
al., 1999).  The MMPs now are categorized on the basis of their structure 
(Egeblad and Werb, 2002) 
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Table 4: Nomenclature and Substrate specificities of MMPs 
(Adapted from Egeblad and Werb, 2002) 
 
 
 
 
 
 
 
 
43 
 
1.7.2 Structure 
Structurally, MMPs have distinct domains with some highly conserved 
regions.  The MMPs have been divided into eight distinct structural groups 
(Figure 4).  These groups have a common basic structure called as the “minimal 
domain”.  The minimal domain consists of an amino terminal signal sequence 
(Pre) which is cleaved by the signal peptidase for facilitating the enzyme‟s entry 
into endoplasmic reticulum (ER).  The Pre-domain is followed by a “Pro” domain 
consisting of a thiol group (-SH) and a furin- cleavage site.  The pro-domain 
connects to a catalytic domain that has a Zn
2+
 atom binding site.  The cysteine 
sulfhydryl group binds covalently to the Zn atom in the catalytic domain.  This 
keeps the enzyme in its latent state. To activate the enzyme, the cystein to Zn 
bond has to be disrupted by either normal proteolytic removal of pro-domain by 
serine proteases or by ectopic disruption of cystein-Zn interaction (cystein switch) 
(Sternlicht and Werb 2001).  Intracellular furin-like proteases that target the furin-
recognition motifs (Fu) in the catalytic domains can cleave the prodomain and 
activate the enzyme intracellularly.  The covalent bond can also be disrupted by 
chemicals such as amino-phenyl mercuric acid (APMA) or other serine proteases 
present in the ECM such as plasminogen activators (PA).  In addition to this 
minimal domain, simple hemopexin domain containing MMPs have at the C-
terminus a hemopexin-like domain that is connected to the catalytic domain by a  
hinge (H) region.  There is a di-sulfide bond (S-S) between the first and the last 
subdomain of hemopexin domain.  This hemopexin-like domain mediates the 
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interaction of the enzyme with other proteins such as the tissue inhibitors of 
metalloproteinases (TIMPs), cell surface molecules and proteolytic substrates.  
The gelatin binding MMPs have collagen-binding type II motifs of fibronectin 
(Fi) present in the catalytic domain.  The furin-activated secretory MMPs have 
furin-proteases recognition motifs in their catalytic domain that cause intracellular 
activation of these MMPs.  Membrane anchored MMPs include MT-MMPs that 
have a transmembrane domain at the C-terminus of the enzyme with a small 
cytoplasmic domain and glycosylphophatidylinositol (GPI) anchor or an amino-
terminal signal anchor (SA).  The MMP-23 (Type II transmembrane MMP) has a 
unique cystein array (CA) and immunoglobulin (Ig)-like domains (Egeblad and 
Werb, 2002). 
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Figure 4 Schematic of different structural categories of MMPs 
The MMPs have been divided into eight categories based on their structure.  All 
MMPs except type II MT-MMPs have a pre domain followed by a pro domain 
consisting of a thiol (SH) group.  Type II MT-MMPs have signal anchor (SA) at 
the N-terminus.  The catalytic domain has Zn atom binding site (Zn) or cystein 
array (CA).  Some MMPs have collagen binding type II motifs of fibronectin (Fi) 
in the catalytic domain.  The pro-domain may also include furin-proteases 
recognition motif (Fu) and Vitronectin (V).  The hemopexin domain is connected 
to catalytic domain by a hinge region (H).  The C-terminus of some MMPs may 
have glycosylphophatidylinositol (GPI) anchor or immunoglobulin (Ig)-like 
domains.  (Adapted from Egeblad and Werb, 2002) 
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Figure 4 
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 1.7.3 Functions of MMPs  
 The function of MMPs in normal physiological conditions is 
controlled and regulated at various levels depending upon the requirement.  A 
balance is maintained between expression of MMPs and their proteolytic 
degradation and inhibition by endogenous inhibitors.  ECM is a biologically 
active and dynamic tissue that is continuously being remodeled and harbors 
various growth factors and signaling molecules.  Any changes brought about in 
ECM affect cell cytoskeletal, adhesion machinery, growth and differentiation.  
Thus, by degrading ECM, MMPs are indirectly influencing these important events 
that shape cell behavior. 
  
Functions of MMPs in normal physiology  
 Although MMPs are traditionally known to have ECM degradation 
as their primary function, recent work in MMP biology has shown that these 
enzymes can perform their proteolytic function to conduct many important 
physiological processes (Page-McCaw et al., 2007).  MMPs can alter the 
epithelial tissue architecture by cleaving cell-cell junctions and cleave ECM 
molecules to clear the path for cell movement.  They can also generate signaling 
molecules from ECM that may act by autocrine or paracrine mechanisms.  For 
example, cleavage of collagen IV α3 chain by MMP-9 yields a new bioactive 
molecule, tumstatin, an anti-angiogenic peptide that binds to integrin receptor 
(Hamano et al., 2003).  MMPs can also cleave latent bioactive molecules altering 
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cell behavior.  For example, cleavage of vascular endothelial growth factor 
(VEGF) modifies its structure and affects its binding affinity to the receptor (Lee 
et al., 2005).  MMPs can deactivate a signaling molecule by cleaving it thereby 
affecting cellular proliferation and motility.  For example, MMP-2 cleaves CXC-
motif ligand-12 (CXCL12) and inactivates it thereby making the host more 
susceptible to HIV-infection (McQuibban et al., 2001).  Cleavage of collagen type 
XVIII results in a fragment, endostatin, which is an anti-angiogenic molecule. 
MMP-1 and MMP-3 cleave insulin-like growth factor binding protein-3 (IGFBP-
3) present in ECM releasing IGF bound to it (Fowlkes et al., 1994).  MMP-1 and 
MMP-3 also degrade proteoglycan perlecan present in ECM to release FGF 
(Whitelock et al., 1996).  MMP-1 mediated type I collagen degradation is 
necessary for epithelial cell migration and would healing in culture models 
(Pilcher et al., 1997).   
 
MMPs also perturb membrane signaling by cleaving growth factors, 
tyrosine kinase receptors, cell-adhesion molecules, cytokines, chemokines and 
other MMPs.  Cleavage of membrane proteins such as E-cadherin and CD44 by 
MMPs results in an increase in cell migration and invasion (Noe et al., 2001; 
Kajita et al., 2001).  Other examples of membrane protein shedding are cleavage 
of syndecan by MT1-MMPs resulting in an increased cell migration (Endo et al., 
2003).  TGF-β is released from its latent state by membrane localized MMP-9 
(Yu and Stamenkovic, 2000).   
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MMPs in bone remodeling 
MMPs are important in bone development and remodeling.  MMP-9 
knockout mice have defects in endochondral ossification, an important step in 
bone development (Vu et al., 1998).  Although MMP-9 is also found to be highly 
over-expressed during bone healing after a fracture, it is not mandatory for 
healing process (Colnot et al., 2003).  MMP-13 is required for bone remodeling 
and the transition from cartilage to bone at the growth plates of long bones 
(Stickens et al., 2004; Inada et al., 2004).  MMP-14 knockout mice are lethal with 
gross defects in connective tissue remodeling (Holmbeck K et al., 1999; Zhou Z 
et al., 2000).  Loss of function mutations in MMPs lead to defects in bone 
developmental diseases.  MMP-2 mutation causes a rare osteolytic syndrome 
(Martignetti et al., 2001).  Mutations in MMP-20 results in tooth enamel defect 
amelogenesis imperfect (Kim et al., 2005).  Mammary gland development during 
puberty requires MMPs mediated degradation of basement membrane and ECM 
for restructuring vascular network (Sternlicht et al., 2006).  
 
MMPs and Vascular development  MMPs mutants do not show any 
defect during embryonic vascular development but postnatal vascular remodeling 
and angiogenesis is severely affected.  MMP-9 mutants show defects in 
angiogenesis at the growth plate of long bones (Vu et al., 1998).  MMP-2 mutant 
mice show reduced vascular growth (Kato et al., 2001) but MMP-14 mutant mice 
lack it altogether (Zhou et al., 2000).  Such defects in vasculature could be 
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attributed to important functions of MMPs such as proteolysis of type I Collagen, 
modification of PDGF and VEGF.  
 
In addition to developmental events, MMPs also contribute in maintaining 
cellular balance during inflammation and wound healing (Parks et al., 2004). 
MMP-7 mutant mice are more susceptible to bacterial infections due to the 
inability of MMP-7 mutant mice to proteolytically cleave and activate 
endogenous antibiotic, pro-cryptdin (Wilson et al., 1999).  MMP-7 mutant mice 
do not show closure of wounds due to absence of MMP-7 mediated cleavage of 
E-cadherins (McGuire et al. 2003).  Injury and infection produce inflammation by 
inducing leukocyte migration towards chemoattractants. The formation of 
chemoattractants requires MMP- mediated cleavage of syndecan-1 ectodomain. It 
has been found that neutrophil migration is defective in MMP-7 mutant mice due 
to the absence of neutrophil attractant CXCL1 (Li et al., 2002).  MMPs can act as 
both pro-inflammatory by recruiting inflammatory cells (Haro et al., 2000) and 
anti- inflammatory by speeding up clearing and removal of inflammatory cells 
(Kumagai et al., 1999).  MMP-12 contributes to emphysema (Morris et al., 2003) 
while MMP-9 is pro-inflammatory in skin (Liu et al., 2005).  MMP-8 protects 
againt skin inflammation (Balbin et al., 2003) and MMP-2 provided similar anti-
inflammatory protection in brain and spinal cord (Esparza et al., 2004).  Thus, 
MMPs regulate inflammation by controlling or inducing it depending on cellular 
microenvironment.    
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MMPs in pathology    
Due to the inherent and primary proteolytic function of MMPs, much 
research has been focused on the role of MMPs in diseases that involve the 
breakdown of connective tissues like rheumatoid arthritis (RA), osteoarthritis, 
periodontitis, inflammation and even cancer.  During inflammation, leukocytes, 
particularly, macrophages synthesize and store these MMPs.  The MMPs released 
from macrophages help in the migration, invasion and extravasation of these 
leukocytes into the tissues thereby causing tissue damage. In addition, there is a 
production of immunogenic fragments of otherwise normal proteins that catalyzes 
auto-immune response (Opdenakker and Van Damme, 1992).  MMPs are 
involved in gastric ulcerations and impaired intestinal wounds (Vaalamo et al., 
1998).  Normal human brain has very low levels of MMPs but these enzymes are 
significantly elevated in various neurological disorders of CNS (Yong et al., 
2001).  The high levels of MMPs can induce neuro-inflammation, demyelination 
of neurons (multiple sclerosis, MS) and disruption of blood-brain barrier with 
serious consequences (reviewed by Yong et al, 2001;  Kieseier et al 1999).  
Several MMPs are found to be expressed at elevated levels in patients suffering 
from auto-immune encephalitis (EAE), particularly MMP-2 and MMP-9 double 
null mice resulted in inability to induce EAE (Agarwal et al., 2006).  Due to 
excessive degradation of ECM, MMPs also contribute to pathologies arising from 
weakening of matrix such as abdominal aortic aneurysm (AAA) (Aziz and 
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Kuivaniemi, 2007) and dialated cardiomyopathy, epidermolysis bullosa 
(Thompson and Parks, 1996). 
 
 The requirement of proteolytic enzymes in invasive tumor growth 
was recognized even before MMPs were discovered (Gersh and Catchpole, 1949).  
The findings from studies conducted by Gersh and Catchpole showed that 
fibroblasts secretions are important for tumor growth and invasion.  Subsequently, 
these secretions were characterized and identified as hyaluronidases, serine 
proteases and MMPs.  The critical role of MMPs, specifically type-IV 
collagenase, in tumor invasion and metastasis was first shown by Lance Liotta 
(Liotta et al., 1980).  The tissue breakdown and remodeling function of MMPs 
helps in events such as tumor invasion, intravasation into circulation, 
extravasation, and migration to metastatic sites and angiogenesis (Folgueras et al., 
2004; Deryugina et al., 2006).  MMPs are over-expressed in a wide range of 
malignancies with strong correlation between their over-expression and tumor 
aggressiveness and prognosis (Egeblad and Werb, 2002).  Studies underlining the 
significance of MMPs in cancer are based on knock-out mouse models.  MMP-7 
null mice show reduced tumor formation (Wilson et al., 1997) while MMP-9 
deficient mice showed decreased melanoma metastasis (Masson et al., 1998).  
MMP-2 deficient mice show reduced melanoma tumor progression and 
angiogenesis (Itoh et al., 1998).  Elevated levels of MMP-2 and MMP-9 
contribute to accelerated tumor growth and progression in oral (Ikebe et al., 
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1999), lung (Kodate et al., 1997), bladder (Papathoma et al., 2000) and ovarian 
cancer (Schmalfeldt et al., 2001).  Increased levels of MT-MMP correlate with 
tumor aggressiveness in laryngeal (Du et al., 1999) and esophageal cancer (Etoh 
et al., 2000).  Several studies show that insertion of a guanine (G) nucleotide at 
position -1607 in the MMP-1 promoter creates a new ETS binding site thereby 
increasing the transcription of the gene (Rutter et al., 1998).  Presence of this 2G 
nucleotide has been shown to increase the promoter activity of MMP-1 in GBM 
(McCready et al., 2005) and invasion in colorectal cancer (Ghilardi et al., 2001) 
and melanoma (Ye et al., 2001).  Increased expreesion of MMP-2 and MMP-9 are 
associated with low survival and increased aggressiveness in brain tumors 
(Jaalijnoja et al., 2000; Choe et al., 2002).   
 
The above findings emphasized a dire need to develop and test clinically 
useful MMP antagonists.  A large number of MMP inhibitors (MMPIs) are being 
tested in various cancers in all the three phases of clinical trials (Sideras et al., 
2006; Robbins et al., 2008).  The first of the MMPIs, Batimastat (BB-94) and 
Marimastat (BB-2516) were pseudopeptide derivatives that mimic the structure of 
collagen and blocked MMP activity by competing for the susbtrate-binding site.  
However, BB-94 had low water-solubility and was not available orally. BB-2516 
affected muculoskeletal systems due to off-target effects (Saghatelian et al., 
2004).  Similar musculoskeletal toxicity has been observed in new MMPIs such 
as prinomastat and BMS-275291 (Hidalgo et al., 2001; Miller et al., 2004).  The 
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clinical trial results have been found to be disappointing either due to side-effects 
even at low dose of drugs or the drug was administered at an advanced stage of 
cancer where MMP inhibition would no longer improve the survival (Robbins et 
al., 2008).  
 
 
1.7.4 Regulation of MMPs 
 To perform the functions during normal physiology and pathological 
conditions, MMPs are tightly regulated at the transcriptional and translational 
levels.  In addition, the function of MMPs is regulated at protein levels by the 
presence of endogenous inhibitors, the tissue inhibitors of metalloproteinases 
(TIMPs).  Hormones, oncogenes, growth factors and cytokines influence the 
transcription of most of MMP genes by interacting with AP-1 sites present in the 
promoter region of MMP genes (Benbow and Brinckerhoff, 1997).  Some MMPs 
(MMP-1, -2, -3, -9 and -12) have single-nucleotide polymorphisms that generate 
an extra ETS binding element site. This site acts synergistically to activate the 
transcription of these genes (Rutter et al., 1998).  Post-transcriptional regulation 
includes stabilization of mRNA of MMP genes by phorbol esters, EGF and PDGF 
(Vincenti et al., 2001).  Most of the members of MMP family, collagenases, 
gelatinases and stromelysins are secreted as zymogens. In the ECM, these 
zymogens are cleaved by other proteases, such as plasmin or by other already 
activated MMPs (Woessner and Nagase 2000).  The TIMPs reversibly inhibit 
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MMPs by binding in 1:1 stoichiometry (reviewed by Sternlicht and Werb 2001).  
Other endogenous inhibitors of MMPs are α-macroglobulins that bind to MMPs 
forming α-macroglobulins/MMP complexes that are cleared by scavenger 
receptor-mediated endocytosis thereby inhibiting MMPs irreversibly (Sottrup-
Jensen and Birkedal-Hansen, 1989).   
 
 
1.8 Matrix Metalloproteinase-1  
Human fibroblast collagenase (MMP-1) was the first MMP to be 
discovered (Gross and Lapiere, 1962), purified and cloned (Bauer, Eisen and 
Jeffrey, 1970; Goldberg et al., 1986).  MMP-1 is also known as interstitial 
collagenase, collagenase-1 or fibroblast collagenase with an official EC number 
3.4.24.7.  The human MMP-1 gene is located on chromosome 11q22.2-22.3 and 
has 10 exons.  It is tightly linked to a cluster of eight other MMPs including 
MMP-3, -7, -8, -10, -12, -13 -20 and -27 (Puente et al., 2003).  Human MMP-1 is 
secreted as a proenzyme with 52 kDa as major form and 57kDa as minor 
glycosylated form.  The cleavage of this pro-peptide yields an active and 
functional MMP-1 with 42 kDa and 47 kDa in sizes respectively (Wilhelm et al., 
1986).  Structurally, MMP-1 has minimal domain structure that has a hydrophobic 
pre-domain directing it to endoplasmic reticulum (ER) for secretion.  The pro-
peptide has a cysteine residue at 73 position in a conserved region PRCGVPD 
bound covalently through a-SH group to the zinc atom in the catalytic site.  The 
56 
 
enzyme becomes activated when this cyteine residue is displaced (cysteine-
switch) by proteolytic cleavage or disruption by chemicals (Sprigman et al., 
1990).  The catalytic domain contains a catalytic zinc bound in the sequence 
HELGHXXGXXH by three His residues (Li et al., 1995).  The crystal structure of 
catalytic domain has five strands of β-sheet and three α-helices (Li et al., 1995).  
The catalytic domain is connected by a linker region to a carboxy terminus 
hemopexin domain.  The hemopexin domain helps in enzyme substrate- binding 
specificity for collagen and interaction with other proteins (Li et al., 1995).   
 
The expression of MMP-1 is low during normal physiology but is elevated 
when active tissue remodeling is needed.  Various growth factors stimulate the 
expression of MMP-1 by up-regulating signal transduction pathways that 
converge to activate AP-1 (activator protein-1) transcription factors.  Mitogen 
activated protein kinase (MAPK) pathways activate ERK1/2, JNK and p38 
protein to induce the expression of AP-1 proteins.  These AP-1 proteins regulate 
the expression of various genes involved in proliferation, development, 
differentiation and tumor progression (Karin et al., 1997).  The MMP-1 promoter 
conatins a TATA box at approximately -30bp, and an AP-1 site at -72 with 
respect to the transcription initiation site (Figure 1.6).  
 
 
 
57 
 
 
 
 
 
 
 
Figure 1.6 Regulatory elements of MMP-1 promoter (Simplistic adaptation 
from Ala-Raho and Kahari, 2005)   
The figure shows important elements in the MMP-1 promoter that are discussed 
in this work.  Activator protein-1 (AP-1), nuclear factor κB (NF-κb), polyoma 
virus enhancer activator-3 (PEA3), STAT binding element (SBE), TATA box 
(TATA), TGF-β inhibitory element (TIE) are transcription factor binding sites.  
An ETS site adjacent to AP-1 trancription factor binding site creates a ras 
responsive element (RRE) at proximal promoter.  In the presence of a single 
nucleotide polymorphism (SNP) at -1607, another RRE is generated at the distal 
promoter. 
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Another AP-1 site is present in the distal promoter at -186 position.  The 
Fos/Jun dimer binds to the AP-1 site which is adjacent to another cis-acting 
sequence called PEA-3 (polyoma virus enhancer A binding protein 3) where 
members of ETS transcription factor family bind (Karin et al., 1997; Sharrocks et 
al., 1997).  AP-1 and ETS transcription factors act synergistically to increase the 
transcription of MMP-1 (Westermarck et al., 1997).  As mentioned earlier, the 
MMP-1 promoter exhibits single-nucleotide polymorphism (SNP).  At position -
1607, there is an extra guanine nucleotide generating ETS transcription factor 
binding site. Together with an adjacent AP-1 site at -1602 position, it forms a ras 
responsive element (RRE) (Rutter et al., 1998).  Oncostatin M enhances 
expression of MMP-1 by activating STAT transcription factors that bind to SBE 
and co-operate with AP-1 elements on MMP-1 promoter (Korzus et al., 1997) 
(Figure 5).  The p53 protein is a transcription factor that binds to a specific 
consensus sequence in the promoter of several genes. In addition, it can also 
interact with proteins to alter their functions. Although, MMP-1 promoter does 
not have a p53 binding element, it has been shown that wild-type p53 down-
regulates MMP-1 transcription (Sun et al., 1999).  Subsequently, it was shown 
that down-regulation of MMP-1 by wild type p53 is due to its interaction with 
p300 protein present in the transcriptional complex (Sun et al., 2004).  The 
cytokine transforming growth factor-β (TGF- β) suppresses MMP-1 transcription 
by binding to TGF- β inhibitory element (TIE) present on MMP-1 promoter at 
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position -245.  Mutations in this element result in induction of MMP-1 
transcription by tissue polypeptide antigen (TPA) (White et al., 2000).   
 
The human MMP-1 mRNA has an AU-rich element which is important 
for its stabilization (Vincenti et al., 1994).  Activation of p38α results in MMP-1 
mRNA stabilization (Reunanen et al., 2002) by activating a zinc-finger protein, 
tristetraprolin that regulates the stability of AU-rich regions of mRNA (Carballo 
et al., 2000).   
 
Activation of latent precursor of MMP-1 by pro-domain proteolytic 
cleavage takes place in a stepwise manner requiring interaction with plasminogen 
activator urokinase and stromelysin (Suzuki et al., 1990).  The serine proteases 
cleave in the middle of pro-domain of MMP-1 generating a 46-kDa intermediate 
form that is further cleaved between Val-67 and Met-68 residues forming a 43kDa 
form.  It needs to be cleaved further for a full activation and this requires cleavage 
by MMP-3, -10 or MMP-7 between Gln-80 and Phe-81 (Ito et al., 1998; Suzuki et 
al., 1990; Imai et al., 1995).   
 
MMP-1 has been found to be over-expressed in normal physiological 
processes like embryonic development and wound healing (McGowan et al., 
1994; Ravanti et al., 2000).  In addition, it is also found be elevated in 
pathological states such as ulcers (Vaalamo et al., 1998) and a wide range of 
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cancers of breast (Wang et al., 1997), colon, stomach, ovary (Murray et al., 1996, 
1998), pancreas (Ito et al., 1999) and skin (Nikkola et al., 2002).  The presence of 
SNP favors the growth and progression of ovarian and colorectal cancers 
(Kanamori et al., 1999; Ghilardi et al., 2001).  MMP-1 has also been found to be 
over-expressed in brain neoplasms (Nakagawa et al., 1994; Nakano et al., 1995; 
McCready et al., 2005).   
 
1.9 Epidermal Growth Factor Receptor Signaling  
 
For a cell to function normally, it requires nutrients and growth factors for 
maintainance and proliferation.  Growth factors communicate with the cell by 
binding to transmembrane receptors presented on the surface of the cell. This type 
of signaling is crucial to the development and survival of a normal cell during 
typical physiological conditions.  In a cancer setting, such growth signaling 
mechanisms go awry; the tight control on the activation and suppression of 
signaling mediated by these growth factors becomes defective.  The cells become 
self-sufficient and constitutively produce these growth factors or they evade 
mechanisms that inhibit the growth signaling (Hanahan and Weinberg, 2000).   
 
Epidermal Growth Factor Receptor (EGFR) is an oncogene that is 
involved in the regulation of several cellular processes mainly cell proliferation, 
survival and migration.  Altered regulation of EGFR activity is an important event 
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that leads to formation and progression of various human malignancies in brain, 
lung, breast, ovary, pancreas and prostate (Hynes and Stern 1994; Saloman DS et 
al., 1995).   
 
 Structurally, EGFR is a 170kDa membrane spanning protein 
consisting of 1186 amino acids. The receptor has an extracellular ligand binding 
domain, a transmembrane domain and a cytoplasmic tyrosine kinase domain 
(Ogiso H et al., 2002; Schlessinger J 2002).  
 
The ErbB or Epidermal Growth Factor (EGF) family of receptor tyrosine 
kinases (RTKs) include four members- EGFR/ErbB1/HER1,   ErbB2/Neu/HER2, 
ErbB3/HER3 and ErbB4/HER4. During normal physiological conditions, the 
activation of EGFR is controlled by the expression and availability of its ligands, 
EGF –related peptide growth factor family (reviewed by Riese and Stern 1998). 
The ligands for these receptors have been divided into three groups- first group 
includes EGF, Amphiregulin (AR) and transforming growth factor-α (TGF-α) that 
bind specifically to the EGFR/ErbB1. The second group consists of heparin-
binding EGF (HB-EGF) and epiregulin (EPR) that bind to both ErbB1 and ErbB4.  
The third group has neuroregulins (NRG) that bind to ErbB4 (NRG-3 and -4) and 
to both ErbB3 and ErbB4 (NRG-1 and -2). There is no direct ligand discovered, 
so far, for ErbB2 suggesting that it is a co-receptor (Holbro T et al., 2003). 
Among its ligands, EGF is an important regulatory factor that is present in 
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abundance in various human cancers, either due to autocrine or paracrine 
signaling pathways. 
 
Binding of EGF to its receptor, EGFR, leads to receptor homo- or hetero- 
dimerization (Olayioye MA et al., 2000) followed by activation of the receptor‟s 
tyrosine kinase domain through trans-tyrosine phosphorylation. The activated 
receptor kinase phosphorylates the tyrosine residues on the C-terminal tail of the 
ErbB receptors. These phosphorylated sites allow the binding of proteins with src-
homology (SH2) domains such as Grb2, shc and Nck. These are adaptor proteins 
that have intracellular docking sites for other proteins such as serine threonine 
kinases that further activate other serine threonine kinases and transcription 
factors (Olayioye MA et al., 2000). Thus, signaling from EGFR leads to an 
amplification of several signaling pathways that alter protein function and gene 
transcription favourable for oncogenesis. The best studied EGFR downstream 
signaling pathways are RAS-RAF-MEK-ERK and PI3K-AKT pathways.  During 
normal conditions, the EGFR signaling is transient and is terminated either by 
phophotyrosine phosphatases or after the receptor is endocytozed and binds to c-
cbl protein that targets it to degradatory pathways (Lipkowitz et al., 2003; 
Muthuswamy et al., 1999).  
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EGFR mediated signaling pathways 
 
1.9.1 MAPK pathway.   
 
Epidermal growth factor receptor stimulation leads to activation of several 
signaling pathways including the mitogen activated protein kinase (MAPK) 
pathway. The MAPKs are a large family of serine-threonine kinases that include 
extracellular signal regulated kinases (ERKs), Stress activated protein kinases 
(SAPK) or c-jun terminal kinases (JNKs) and p38 mitogen-activated protein 
kinases. These kinases are phosphorylated and activated by MAPK kinases 
(MKKs) which in turn are activated by MKK kinases (MKKKs) (Johnson GL et 
al 2005). Upon EGF stimulation, the EGFR binds to adaptor proteins Grb2 or shc 
and recruits son-of-sevenless (SOS) protein (Wu J et al 1993). The SOS protein at 
the plasma membrane causes a small G protein RAS to release its GDP and 
exchange it for GTP thereby activating it. The activated RAS targets its 
downstream protein, Raf-1, which is a MKKK. Raf-1 kinase activates and 
phosphorylates MKK, MEK1/2, that in turn activates ERK1/2.  ERK1/2 is a 
MAPK and it activates various other proteins such as ribosomal S6 protein kinase 
(Rsk), MSK, cPLA2, c-Myc, Ets-2 and Elk leading to the increases gene 
transcription of anti-apoptotic proteins (Bcl-2 and inhibitor of apoptosis, IAPs) 
(reviewed in Henson and Gibson, 2006).   
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1.9.2 PI3 kinase/AKT pathway. Phosphatidylinositol- 3 kinase 
(PI3-kinase) protein has an SH2 domain that is needed for interaction with the 
EGFR after its stimulation.  PI3-kinase is recruited to the plasma membrane 
where it catalyzes the transfer of a phosphate group from ATP to 
phophatidylinositol generating a 3‟- phophatidylinositol phosphate (PIP3). This 
process is reversed by phosphatase and tensin homolog protein (PTEN).  PIP3 
binds to proteins with pleckstrin homology (PH) domains. AKT (also called as 
protein kinase B, PKB) is a serine-threonine kinase that has PH domain and binds 
to PIP3 and gets phosphorylated. AKT has been regarded a key player in the 
survival pathway of a cell by acting on its downstream targets that are categorized 
into apoptotic proteins, transcription factors and protein kinases. AKT activates 
transcription factors- NFκB, CREB and HIF-1α to increase the transcription of 
anti-apoptotic proteins.  AKT phosphorylates inhibitor of NFκB kinase (IKKα/β), 
which phosphorylates and inactivates IκB. IκB dissociates itself from its NFκB 
bound state and gets degraded releasing NFκB for nuclear translocation (Song et 
al., 2005). EGFR inhibition sensitizes cells to apoptosis by de-activating AKT 
(Longva et al., 2005).  Glycogen synthase kinase- 3 is AKT downstream target 
that gets inactivated by phosphorylation leading to reduced transcriptional activity 
and metabolism (reviewed by Woodgett, 2005). AKT phosphorylates and 
activates mTOR, mammalian target of rapamycin, a serine-threonine kinase. 
mTOR activates ribosomal S6 kinase and eukaryotic initiation factor 4E- binding 
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protein 1 (4E-BP1) leading to an overall increases survival and increased 
translational activity in the cell (Sun et al., 2005).   
 
Evidence of cross talk signaling between PI3K and MAPK has been 
reported.  Hyper-phosphorylated AKT also phosphorylates and inactivates Raf 
thereby attenuating MAPK singaling (Zimmerman and Moelling, 1999).  In 
addition, PI3K also activates RAS leading to the activation of MAPK pathway 
(Jun et al., 1999).   
 
1.10 EGFR biology in GBM  
Published findings show that EGF stimulates tumor growth, invasion and 
migration in an in-vitro glioma model (Lund-Johansen et al., 1990).  EGFR over-
expression is associated with resistance to radiation in malignant GBM cells 
(Chakravarti et al., 2002) and poor response to radiation therapy in patients with 
GBM (Barker et al., 2001).  Radiation leads to EGFR activation and upregulation 
of MAPK and PI3K pathways which then lead to an increased cytoprotective 
response (Schmidt-Ullrich et al., 1997; Dent et al., 2003) and accelerated cell 
proliferation (Carter et al., 1998).  Inhibition of EGFR radio-sensitizes and 
induces apoptosis in malignant glioma (Birgit et al., 2008) leads to decreased 
invasion, inhibition of U251 glioma cell growth (Stea et al., 2003) and 
cytotoxicity in U87 glioma cell line (Yamoutpour et al., 2008).  The interruption 
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of MAPK and PI3K/Akt signaling pathways may provide mechanisms for 
inhibition of tumor growth and overall survival.  
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AIMS 
 
The focus of this dissertation was to examine the function of MMP-1 in 
GBMs.  Although, the primary substrate for MMP-1, collagen, is lacking in 
GBMs, there is a significantly increased expression of MMP-1 in GBM as 
compared to normal physiology.  In recent years, mounting evidence shows that 
MMPs do not just degrade ECM; they perform important functions by cleaving 
bio-active molecules present in the ECM to activate various oncogenic signaling 
pathways.  Extensive literature suggests the involvement of MMP-1 in various 
pathologies including cancer.  Therefore, the regulation of this particular enzyme 
is paramount for better therapy.  In GBMs, a majority of patients have EGFR 
signaling pathway abnormalities.  We wanted to examine the correlation between 
EGFR-mediated tumor aggressiveness and MMP-1 expression. Chapter 3 focuses 
on the regulation of MMP-1 by EGFR and the signaling pathways associated with 
it. 
 
 
 
 
 
 
 
69 
 
 
 
 
 
CHAPTER 2 
 
 
Matrix Metalloproteinase-1 over-expression in human 
glioblastomas: Implications in glioma cell invasion 
Anand M, Mullet E, McCready J, Abd-Elfattah N, Fuller CE, Broaddus WC, and 
Fillmore HL 
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2.1 Abstract 
 Glioblastoma Multiforme (GBM) is the most common form of primary 
malignant brain tumor with a median survival of approximately one year post-
diagnosis.  The highly invasive characteristic of GBM, an important factor 
contributing to the failure of therapies, involves the action of proteolytic enzymes 
such as matrix metalloproteinases (MMPs).  MMP-1 is a key enzyme that leads to 
invasion in many cancers by degrading extra-cellular matrix (ECM) proteins and 
cleaving latent bioactive molecules that aid in the up-regulation of pro-invasive 
proteins.  We examined the expression of MMP-1 in human GBM tissue 
specimens and its function in GBM cell lines.  The protein levels of MMP-1 in 
GBM patient samples were analyzed using Enzyme-linked immunosorbent assay 
(ELISA) and immunohistochemistry.  Down-regulation of MMP-1 was performed 
in T98G glioma cells by transient transfection with MMP-1 siRNA and MMP-1 
over-expression was achieved in U251MG and U87MG cell lines by stable 
transfection of a MMP-1-pIRES cDNA vector.  Invasion and cell proliferation 
assays were conducted.  We observed that MMP-1 protein levels are elevated in 
human GBM tissue as compared to normal brain.  Immunohistochemistry of 
patient samples indicated that MMP-1 protein is present in both glioma cells and 
endothelial cells.  Inhibition of MMP-1 expression in T98G cells by siRNA 
resulted in a significant decrease in invasion compared to controls.  Glioma cells 
engineered to stably over-express MMP-1 showed a significant increase in 
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invasion compared to controls.  Thus, we can conclude that MMP-1 is over-
expressed in human glioma tissue and can influence glioma cell invasion in vitro 
suggesting its importance in glioma biology.  
 
 
2.2 Introduction 
Despite significant improvements in the diagnosis and treatment of 
patients with glioblastoma multiforme (GBM), this primary brain tumor remains 
essentially incurable. Initial treatment usually includes surgical resection of the 
tumor mass, followed by radiation and chemotherapy.  In virtually all cases the 
tumor recurs, usually near the margins of the previous resection, often in a form 
that is more resistant to subsequent therapies.  A key feature that underlies the 
malignant behavior of this disease is the ability of glioma cells to aggressively 
infiltrate surrounding brain tissue (Zhu and Parada, 2002; Giese et al., 2003; Rao 
et al., 2003).  The presence of invasive cells in the brain surrounding the primary 
tumor explains the tendency of these tumors to recur at these margins.  Growth 
factors, extracellular matrix molecules, and proteases are secreted from both 
tumor and normal brain cells, and are likely to interact in complex ways to 
contribute to the highly invasive behavior of GBM cells.  Tumor cell invasion 
involves interactions with and degradation of molecules of the extracellular 
matrix followed by active cell migration.  Matrix metalloproteinases (MMPs) are 
important proteolytic enzymes that have been implicated in the invasion process 
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in a wide variety of cancers (Egeblad and Werb, 2002).  With over 25 members, 
MMPs are classified as stromelysins (that cleave fibronectin and proteoglycans), 
interstitial collagenases (that cleave triple helical regions of fibrillar collagens: 
Types I, II, III, VII, VIII and X) and gelatinases (that cleave denatured collagen, 
fibronectin, elastin and collagens:  Types IV, V, VI, VII and X).  MMPs are 
tightly regulated at the transcriptional and translational levels and once secreted 
from tumor or host cells, they can activate other proteases.   
 
Accumulating evidence suggests a correlation between elevated 
expression of MMPs and glioma progression. Published findings show that MMP-
2 (Gondi et al., 2009; Kargiotis et al., 2008; Yamamoto et al., 1996; Lampert et 
al., 1998; Vince et al., 1999), MMP-7 (Vince et al., 1999), MMP-9 (Ezhilarasan et 
al., 2009; Lakka et al., 2005; 2002), MMP-14, MMP-15 (Fillmore et al., 2001) 
and MMP-16 (Xia et al., 2009) are involved in brain tumor biology.  Of the 
matrix metalloproteinase family, MMP-2, MMP-14 and MMP-9 have been the 
most extensively studied in brain tumors whereas MMP-1 has been less 
characterized.  Limiting the role of MMP-1 to collagen breakdown may have led 
to a lack of study in the brain, where there are not significant quantities of 
collagen type I. MMP-1, also known as collagenase I, was first described by 
Jerome Gross in the early 1960s (Gross and Lapiere 1962; McCawley et al., 
2001).  In addition to cleaving type I collagen, MMP-1 also activates MMP-2 
(Vihinen et al., 2002) and stimulates MMP-9 release from cultured neural cells 
73 
 
and macrophages (Conant et al., 2002).  Other than type I collagen, MMP-1 can 
cleave aggrecan, laminin, tenascin and fibrin.  It is also known to cleave latent 
forms of cytokines such as pro-TNF- (McCawley et al., 2001).  We have 
reported that there is a significant increase in MMP-1 mRNA levels in tumor 
samples from patients with GBM relative to normal brain (McCready et al., 
2005).  MMP-1, which is not typically expressed in normal brain (McCready et 
al., 2005), has been shown to be elevated in glioma (Hodgson et al., 2009) and 
correlates with tumor grade and survival time (Stojic et al., 2008; Nakano et al., 
1995).  Herein we use an ELISA assay and immunohistochemical techniques to 
examine the expression of MMP-1 protein in human glioma tissue.  To investigate 
the role of MMP-1 in glioma cell invasion, we have performed Matrigel-invasion 
assays in glioma cell lines that were manipulated by stable over-expression and 
transient siRNA-mediated inhibition of MMP-1.  Results demonstrate that MMP-
1 expression promotes and MMP-1 suppression inhibits glioma cell invasion.  
 
2.3 Materials and Methods   
 
Cell Culture  
 Human GBM cell lines (T98G, U251MG and U87MG) were obtained 
from American Type Culture Collection (ATCC, Manassas, VA, USA) and 
maintained in Dulbecco‟s Modified Eagle Medium (DMEM Invitrogen, Carlsbad, 
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CA, USA) supplemented with 4.5 g/l D-glucose, 1% penicillin/streptomycin 
(Invitrogen) and 10% Fetal Bovine Serum (FBS) (Gemini Bio-Products, West 
Sacramento, CA, USA).  Cells were incubated in a humidified incubator at 37°C 
with 5% CO2 in Nunclon 75cm
2
 culture flasks (Nunc, Germany) and harvested 
with 0.25% Tryspin-EDTA (Invitrogen).  
 
Tissue samples   
Tumor tissue was obtained at the time of craniotomy and was dissected 
free of adventitial material, snap-frozen in liquid nitrogen, and maintained in a 
tissue bank at -80
0
C, in accordance with a protocol approved by the VCU 
Institutional Review Board.  Confirmation of diagnosis of GBM was determined 
by a staff neuropathologist.   
 
Enzyme-linked immunosorbent assay   
Total protein was extracted from 6 normal brain samples and 26 glioma 
samples using Tissue Protein Extraction Reagent (T-PER, Pierce, IL) and 
quantified using the Coomassie Plus Protein Assay Reagent Kit (Pierce, IL). 10μg 
of total protein was subjected to a sandwich enzyme immunoassay.  Capture and 
detection antibodies were used (CLMABMMP1, ACL2MMP1, Cedar Lane, 
Canada) and incubation was carried out at room temperature for 2 hours.  After 
the incubation, the plate was washed 5 times with PBS followed by addition of 
tetramethylbenzidine.  The plate was incubated in the dark at room temperature 
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for 30 minutes, and the reaction was stopped by addition of 2.5N H2SO4.  The 
absorbance at 450 nm was measured by a microplate reader (Molecular Devices, 
Inc., Sunnyvale CA).  
 
Immunohistochemistry  
The MMP-1 immunohistochemical (IHC) staining was performed using a 
rabbit anti-MMP-1 antibody (Abcam catalog# ab38929, Cambridge MA) at a 
dilution of 1:100.  Slides were deparaffinized through 3 changes of Xylene for 5 
minutes each and rehydrated through 2 changes of 100% reagent alcohol for 3 
minutes each, 1 change of 95% reagent alcohol for 3 minutes, and 1 change of 
80% reagent alcohol for 3 minutes.  Endogenous peroxidase activity was blocked 
by incubation in 0.3% hydrogen peroxide at room temperature for 5 minutes.  The 
IHC stain was performed using Heat Induced Epitope Retrieval (HIER), 
consisting of a 20 minute incubation in Target Retrieval solution, pH 6 (Dako 
Corporation, Carpinteria CA) and a 20 minute cooling period.  Slides were placed 
on an Autostainer Plus
TM
 (Dako Corporation, Carpinteria CA), on which all 
subsequent incubations were performed at room temperature and all washes 
consisted of a rinse with Wash Buffer (Dako Corporation, Carpinteria CA).  
Nonspecific binding sites were blocked with Serum Free Universal Protein Block 
(Dako Corporation, Carpinteria CA) for 5 minutes.  Slides were then washed and 
incubated with the primary antibody at the above-mentioned dilution in Antibody 
Diluent with Background Reducing Agents (Dako Corporation, Carpinteria CA) 
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for 1 hour.  An incubation with biotinylated goat anti-rabbit secondary antibody 
(Vector Laboratories, Burlingame, CA), dilution 1:500 in previously noted 
antibody diluent was followed by a wash, and subsequent incubation in 
Envision+
TM
 Dual Link (Dako Corporation, Carpinteria CA) for 30 minutes.  
Slides were washed again and incubated for 10 minutes in DAB+ 
(diaminobenzidine--Dako Corporation, Carpinteria CA).  Slides were removed 
from the Autostainer Plus
TM
 and counterstained with Gills III Hematoxylin (Poly 
Scientific, Bay Shore, NY), blued in tap water, rinsed in deionized water, 
dehydrated through 1 change of 80% reagent alcohol for 3 minutes, 1 change of 
95% reagent alcohol for 3 minutes, and 3 changes of 100% reagent alcohol for 3 
minutes each.  The dehydration was followed with 3 clearing changes of Xylene 
for 5 minutes each and coverslipped using Tissue Tek Glas Mounting Media 
(Sakura, Torrance, CA) and 24x55 #1 coverglasses (Cardinal Health, McGaw 
Park, IL).  Images were obtained using an Olympus DP72 digital camera 
(Olympus America Inc, Center Valley, PA) mounted on a Nikon Eclipse E600 
microscope (Nikon Instruments Inc, Melville, NY).  
 
MMP-1 siRNA transient transfection  
T98G cells were transfected with Silencer pre-designed siRNAs against 
MMP-1: siRNA ID 1157 sense, GGUAUGAUGAAUAUAAACGtt (Ambion, 
Austin, TX, USA), targeting between 1265 to 1285 bases in the human MMP-1 
transcript.  The cells were plated in complete media (without antibiotics) in six-
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well plates at a density of 200,000 cells per well.  At 80% confluence, media were 
removed from the cells and the wells were washed with PBS followed by addition 
of 800μl per well of Opti-MEM I reduced serum medium (Invitrogen).  
Oligofectamine transfection reagent, Opti-MEM I and siRNA or scrambled RNA 
(at concentrations of 30nM) mixtures were made and incubated at room 
temperature for 20 min.  Then cells were treated with reaction mixtures of 
scrambled siRNA and predesigned siRNA against MMP-1.  The six well plates 
were kept on a shaker at 37°C for 6 hours. Opti-MEM I supplemented with 30% 
FBS was added (500 μl per well) for overnight incubation.  Complete media were 
added the next day (500μl per well).  At the end of 48 hours, media were replaced 
with serum-free media for overnight incubation at 37°C.  Proteins were extracted 
from conditioned media and cells after the overnight incubation.  
 
Stable over-expression of MMP-1   
U251MG cells were stably transfected with the pIRES-GFP-MMP-1 
vector containing sequences for green fluorescent protein and MMP-1, as well as 
G418 resistance.  One million cells were transfected with 1μg DNA using the 
Oligofectamine transfection method according to the manufacturer‟s protocol 
(Invitrogen).  Three days after transfection, medium containing 500μg per ml 
Geneticin (G418, GIBCO) was added to the U251-vector control and MMP-1 
over-expressing transfectants.  The Geneticin–resistant cells were selected and 
grown for further experiments.  Afterwards, these cells were stably maintained in 
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complete DMEM supplemented with 400μg per ml Geneticin.  Over-expression 
of MMP-1 was confirmed by immunoblot studies as shown in experimental 
results below.  
 
Immunoblot 
Cell lysates and conditioned media were collected from the GBM cell 
lines-T98G, U251MG and U87MG.  In these experiments, the conditioned media 
were collected and concentrated from a volume of 4ml to 250μl using Amicon 
centrifugal filters (Millipore).  For preparation of cell lysates, the cells were 
treated with ice cold RIPA buffer (150 mM NaCl, 50mM Tris, 1% NP-40, 0.5% 
Sodium Deoxycholate, 0.1% SDS) supplemented with protease inhibitors 
(Calbiochem).  The lysates were centrifuged at 14000 rpm for 20 min after 
shearing with 26 gauge needles.  Protein concentrations were determined using 
DC Protein Assay (Bio-Rad, Hercules, CA, USA)  
 
Expression of MMP-1 protein levels was determined by immunoblot 
analysis.  Proteins isolated from conditioned media (10ug) and cell lysates (30μg) 
were separated  in 4-12% polyacrylamide –bis-Tris gels (Invitrogen, Carlsbad, 
USA) and transferred to a 0.45μm nitrocellulose membrane (Invitrogen, Carlsbad, 
USA).  After blocking in 5% milk in TBST (50mM Tris base, 150mM NaCl, 
0.05% (v/v) Tween 20), the membranes were incubated with mouse monoclonal 
anti-MMP-1 antibody (R & D Systems, Minneapolis, MN, USA at 1:200 dilution) 
79 
 
in the blocking solution. Rabbit polyclonal anti-cyclophilin A antibody 
(Millipore, Billerica, MA, USA) was used to quantify any variability in loading 
onto the polyacrylamide gels.  After washing the membranes in TBST, they were 
incubated with horseradish peroxidase –conjugated secondary antibodies: goat 
anti rabbit IgG and goat anti mouse IgG, (Rockland Immunochemicals, 
Gilbertsville PA, USA) both diluted 1:5000 in 5% milk-TBST solution.  Blots 
were visualized with exposure of autoradiographic film using an enhanced 
chemiluminescent system (ECL, GE Healthcare).  The developed films were 
scanned and densitometry was performed using ImageJ.  
 
Matrigel Invasion Assays  
Invasiveness of GBM cell lines was determined using transwell inserts 
(Corning Incorporated, USA) with 8μm pores.  The inserts were coated with 
growth factor reduced Matrigel (BD Biosciences, CA, USA) at a concentration of 
100 μg per filter diluted in cold serum-free DMEM for 30 minutes at 37°C 
incubator.  600 μl of 10% serum containing medium was added to the bottom 
chamber.  The cells at a density of 1x10
6 
cells per ml were added to the top 
chamber and incubated at 37°C for 48 hours.  At the end of incubation, the cells 
that passed through the Matrigel into the bottom chamber were counted under the 
microscope from four random fields per transwell.  Three replicates for each 
experimental condition were analyzed.  
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Cell Proliferation Assays   
Cell proliferation was measured using the CellTiter-Glo luminescent Cell 
Viability ATP assay (Promega). 1000 cells per 100μL media were plated in 6 
replicates per condition in white-walled 96 well plates (Corning Life Sciences).  
At the end of each time point (days 0, 1, 3 and 5), 100 μl per well of Cell Glo 
solution was added directly to the wells containing cells, with gentle shaking at 
room temperature for 10 minutes followed by incubation at 4°C for 10 min.  A 
standard curve of known ATP concentrations was generated for each assay.  
Luminescence was detected using a Fluostar Optima plate reader (BMG Labtech, 
Durham, NC, USA), and ATP estimated based upon standard curve luminescence.  
The measurement of number of cells was correlated with the luminescence 
obtained from serial dilutions of cell-counts from each cell line.  
 
Statistical Analysis   
Data were evaluated by comparing the means and SEM of replicate 
experiments.  Data are expressed as the mean and SEM of at least three 
independent experiments.  Statistical analysis was done using an unpaired 
Student's t test. P < 0.05 was considered significant. 
 
 
 
 
81 
 
2.4 Results 
Matrix metalloproteinase-1 is over-expressed in human 
GBM tissue specimens   
To determine the expression levels of MMP-1 in GBM, we analyzed 
protein from 6 normal brain samples and 26 GBM patient samples.  Of the 26 
GBM samples tested, the majority of samples had MMP-1 levels ranging from 12 
to 54 ng per 10 μg of total protein and only two had no detectable levels of MMP-
1.  There were no detectable levels of MMP-1 in normal brain tissue samples 
(Figure 2.1A).  To confirm the expression and localization of MMP-1 in GBM 
patients, we performed immunohistochemistry with paraffin-embedded sections 
of three human GBM samples using an antibody against MMP-1.  
Immunostaining confirmed the expression of MMP-1 in all of the GBM tissue 
samples (Figure 2.1B), particularly in the perivascular regions of the tissues.  
There was no detectable MMP-1 expression in normal brain adjacent to tumor 
(Figure 2.1B). 
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Figure 2.1 MMP-1 protein expression in GBM. A) MMP-1 protein levels 
in normal versus GBM patient samples as measured by ELISA. B) MMP-1 
expression in three representative GBM paraffin-embedded tissue samples.  
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MMP-1 inhibition by siRNA leads to a decrease in glioma 
cell invasion  
 
MMP-1 has been established as an important contributor to invasion in 
other malignancies.  To examine if it has a pro-invasive function in glioma, we 
first used siRNA to specifically inhibit MMP-1.  The T98G cell line was used for 
these inhibition studies due to the presence of a high basal level of MMP-1.  
Treatment with 30nM MMP-1 siRNA inhibited the expression of MMP-1 in the 
T98G cell line as observed in both conditioned media and cell lysates (Figure 
2.2A).  Densitometric analysis demonstrates a decrease in MMP-1 
immunoreactivity in both conditioned media (-76%) and cell lysates (-69%) 
(Figure 2.2B).  In a parallel experiment, invasive capacity of the T98G cells 
treated with MMP-1 siRNA was examined.  There was a significant decrease in 
glioma invasion in cells that were treated with MMP-1 siRNA compared to 
scrambled RNA-treated and no treatment controls (Figure 2.3C).  To determine 
whether the viability of cells treated with siRNA was affected, we performed 
growth curves of control and siRNA-treated T98 cells using an ATP-based 
viability assay (Figure 2.3D).  There was no difference in ATP detection among 
the various groups indicating that the siRNA does not affect the in vitro growth of 
T98G cells.   
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Figure 2.2 Transient inhibition of MMP-1 using siRNA leads to a 
decrease in glioma invasion.  A) Representative immunoblot of T98G cell lysates 
(CL) and conditioned medium (CM) from cells treated with MMP-1 siRNA using 
Oligofectamine at 30nM concentration in T98G cells, NT (no treatment), Scr 
(scrambled control), Transfection reagent (Oligofectamine) and MMP-1 siRNA, 
cyclophilin (cyc) is used as loading control for cell lysates.  B) Densitometric 
analysis of conditioned media and cell lysates (normalized to cyclophilin control) 
from scrambled and siRNA treated samples. Data is representative of three 
independent experiments and densitometric analysis is conducted across three 
experiments (n=3).  C) Matrigel- invasion assay shows the comparison of the 
number of cells that invaded through a 100 μg matrigel (per filter) in a 48 hour 
timeperiod between scrambled and MMP-1 siRNA treated T98G cells, * p value 
< 0.005.  D) Cell Proliferation Assay performed using Cell-Titer Promega kit in 
T98G cells treated with scrambled (scr) and MMP-1 siRNA over 0, 1 and 3 days 
time points show no difference in viability in MMP-1 siRNA treated T98G cells 
compared to the scrambled treated control T98G cells.  Data is mean of three 
separate experiments (n=3). 
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MMP-1 over-expression leads to increased invasion 
 Based on the results obtained from the inhibition studies we created 
U251MG and U87MG cell lines that stably over-express MMP-1 (Figure 2.3A).  
In normal culture conditions, these cell lines have low basal expression of MMP-
1. Following confirmation of over-expression of MMP-1 by immunoblots, the 
parental, vector control and MMP-1 over-expressing cells were examined for 
invasive potential in matrigel-based invasion assays.  We found that MMP-1 over-
expressing cell lines were significantly more invasive than the controls (Figure 
2.3B).  There was approximately 50% increase in invasion in MMP-1 over-
expressing U87 cell lines over U87 vector control (p <0.05).  In addition, U251 
cells over- expressing MMP-1 were 68% more invasive than the vector controls 
(p<0.05) (Figure 2.3B).  To determine if the increased invasion was due to an 
increase in cellular proliferation, we performed in-vitro cell proliferation assays 
with the U251MG and U87MG stably transfected cells along with the controls.  
We found that there was no observable difference in the proliferation rates among 
the parental, vector controls and MMP-1 over-expressers (Figure 2.3C).  These 
results indicate that MMP-1 increases glioma cell invasion in vitro and suggest 
that MMP-1 may play a role in GBM invasion. 
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Figure 2.3 A). U251MG and U87MG cells were stably transfected with a 
pIRES-GFP-MMP-1 cDNA vector with neomycin resistance. Immunoblots 
confirm the over-expression of MMP-1 in conditioned media and cell lystaes 
(cyclophilin used as loading control).  B) Invasion assays using U251MG and 
U87MG parentals (no treatment), vector control (pIRES-GFP with neomycin 
resistance) and MMP-1 over-expression were performed. There is a significantly 
increase in invasion in MMP-1 over-expressing U251MG and U87MG cells as 
compared to the controls (vector control and parental).  Data is representative of 
three independent experiments, p*<0.05 (U251MG MMP-1 over-expressing cells 
as compared to the vector-control), p#<0.05 (U87MG MMP-1 over-expressing 
cells as compared to the vector-control) (n=3).  C) Cellular proliferation assays 
were performed using a Cell-Titer Promega kit. No difference was observed in the 
cell proliferative ability among the three sample groups in each cell line. Data 
shown is mean of three separate experiments, n=3. 
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2.5 Discussion  
In this study, we examined the role of MMP-1 in glioma cell invasion and 
in-vitro cell proliferation.  It is known that GBMs express MMP-1 (Hodgson et 
al., 2009; Stojic et al., 2008; McCready et al., 2005; Nakano et al., 1995); 
however, its specific role in high-grade glioma pathology is not yet determined.  
Our results demonstrate that MMP-1 promotes the invasive potential of U251MG 
and U87MG GBM cell lines, and inhibition of its expression in T98G reduces 
glioma invasion.  The ability to affect invasion is not due to a change in cellular in 
vitro proliferation as this is not altered in cells with MMP-1 over-expression or 
inhibition.   
 
Invasion of brain tumor cells is one of the hallmark challenges that face 
glioma-targeted therapies.  During invasion, proteases released from both host and 
tumor cells may interact with the extracellular matrix (ECM) molecules to 
facilitate cell dispersal.  Published findings report that gliomas express several 
proteases including members of the matrix metalloproteinase (MMP) family 
(Fillmore et al 2001; Bellail et al., 2004; Van Meter et al., 2001, Nuttall et al., 
2003).  Matrix metalloproteinase-1 is an important contributor to invasion and 
metastasis in a variety of cancers (Egeblad and Werb, 2002; Vihinen et al., 2002; 
Ala-Aho and Kahari, 2005; Nikkola et al., 2005; Ghilardi et al., 2001; 
Brinckerhoff et al., 2000; Wyatt et al., 2005; Behrens et al., 2001; Murray et al., 
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1996).  Since there is a low abundance of type I collagen in the brain, the role of 
MMP-1 in brain tumor invasion likely lies in a function distinct from its ability to 
degrade collagen.  In addition to its role of degrading collagen, MMP-1 can also 
cleave latent precursors of bioactive molecules present in the ECM (Sternlicht and 
Werb, 2001; Brinckerhoff and Matrisian, 2002).  These cleaved activated 
molecules such as growth factors bind to their receptors leading to signaling 
cascades that promote tumorigenesis including pro-invasive, proliferative, and 
anti-apoptotic mechanisms.  In this context, we speculate that MMP-1 mediates 
brain tumor invasion largely by mechanisms other than by degradation of type I 
collagen.   
 
Recently, it has been shown that MMP-1 directly cleaves protease-
activated receptor-1 (PAR-1), a G-protein coupled receptor (GPCR) and promotes 
invasion in breast cancer (Boire et al., 2006) and melanoma (Blackburn et al., 
2009).  PAR-1, also a pro-angiogenic receptor, has been proposed to be involved 
in the invasion and metastasis of cancers of breast, ovarian, pancreas, prostate and 
melanoma (Boire et al., 2006; Granovsky-Grisaru et al., 2006; Blackburn et al., 
2009; Agarwal et al., 2008; Salah et al., 2007) by triggering G-protein signaling 
mechanisms in the cell that include increased calcium signaling, cell, migration, 
gene transcription and mitosis.  We speculate that such cleavage and activation of 
PAR-1 by MMP-1 may form one of the mechanisms that lead to increased glioma 
invasion.  PAR-1 activation by MMP-1 not only stimulates pro-invasive GPCR 
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signaling but also transactivates an important growth factor receptor, EGFR [42-
44].  In summary, MMP-1 may perform its pro-invasive functions dually by a) 
indirectly up regulating pro-invasive factors in ECM and b) cleaving and 
activating PAR-1 and downstream signaling.  
 
Taken together, these findings suggest that inhibition or down-regulation 
of MMP-1 may be beneficial in developing a more effective therapeutic approach 
to improve the treatment of gliomas.   
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Epidermal Growth Factor induces metalloproteinase-1 (MMP-
1) expression and invasion in glioma cell lines via the MAPK 
pathway. 
 
Monika Anand, Timothy E Van Meter, and Helen L Fillmore 
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3.1 Abstract 
Glioblastoma Multiforme (GBM) is an aggressive cancer with a poor 
survival rate.  A key component that contributes to the poor prognosis is the 
capacity of glioma cells to invade local brain tissue in a diffuse manner.  Among 
various proteases that aid in the process of invasion, matrix metalloproteinase-1 
(MMP-1) has been identified as an important contributory factor in various 
cancers.  Apart from its traditional role in cleaving its primary extra-cellular 
matrix (ECM) substrates, and like other members of the matrix metalloproteinase 
family, MMP-1 can activate latent forms of bio-active molecules initiating 
downstream pro-invasive and pro-oncogenic signaling mechanisms.  MMP-1 
expression is regulated by several growth factors including epidermal growth 
factor (EGF).  Due to the fact that the epidermal growth factor receptor (EGFR) is 
aberrantly overexpressed in GBM, we wanted to examine in greater detail the 
signaling mechanisms by which MMP-1 expression and invasion is driven by 
EGF in GBM cells.  Treatment of T98G cells with EGF resulted in an induction 
of MMP-1 expression following EGFR activation.  Inhibition of EGFR by either 
pharmacologic or genetic approaches abrogated this induction.  Repression of the 
mitogen activated protein kinase (MAPK) signaling led to the inhibition of EGF-
induced MMP-1 whereas the PI3-kinase/AKT signaling was not associated with 
EGFR-mediated MMP-1 induction.  Inhibition of EGFR signaling also led to a 
decrease in T98G invasion.  These data suggests that EGFR mediated MMP-1 
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regulation is mainly via the MAPK pathway in T98G cells and inhibition of 
EGFR and MMP-1 results in a decrease in T98G cell invasion.  
 
3.2 Introduction 
 
Glioblastoma Multiforme (GBM) is the most common and malignant 
primary brain tumor (CBTRUS, Statistical Report, 2010).  Despite multimodal 
treatments involving surgical resection, chemotherapy and radiotherapy, the 
survival rate is dismal, with a mean survival of approximately 11 months.  One 
major reason for the failure of therapies is the aggressive infiltration and invasive 
nature of the tumor cells.  Mechanisms of invasiveness are therefore important 
parameters for studies in the identification of potential therapeutic targets for this 
incurable cancer.   
 
Growth factors, extracellular matrix molecules, and proteases are secreted 
from both tumor and normal brain cells, and contribute to the highly invasive 
behavior of GBM cells.  Tumor cell invasion involves interactions with and 
degradation of molecules of the extracellular matrix (ECM) followed during 
active cell migration.  Matrix metalloproteinases (MMPs) are important 
proteolytic enzymes that have been implicated in the process of invasion in a wide 
variety of cancers (Egeblad and Werb, 2002).  
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 Amplification, over-expression and mutations in EGFR gene are common 
events (affecting ~ 65% of cases) in gliomas tumorigenesis, particularly in de-
novo GBM (Libermann et al., 1985; Wong et al., 1992; Frederick et al 2000).  
EGFR is involved in the regulation of cell proliferation, motility and survival of 
cells and an imbalance in the EGFR-ligand signaling axis can give rise to 
neoplastic transformation via 1) increased production of EGFR ligands and 
autocrine regulation, 2) increased expression of EGFR, 3) EGFR mutations that 
lead to constitutive activation of the receptor, or 4) defects in the normal EGFR 
down-regulatory processes (Zandi et al., 2007).  
 
Mutations in the extra-cellular domain are particularly frequent in GBM, 
especially the EGFRvIII mutation, also called as de2-7EGFR or δ2-7EGFR 
(Zandi et al., 2007).  EGFRvIII mutation results from an in-frame deletion of 
exons 2 to 7 that encode subdomain I and 2/3
rd
 of subdomain II (Wong et al., 
1992).  The truncated receptor lacks the N-terminal ligand binding area, changing 
the conformation of the receptor to allow autophosphorylation and constitutive 
activation (Ekstrand et al., 1994).  This activation is enough to induce and sustain 
oncogenic signaling (Chu et al., 1997) but not sufficient to be recognized by its 
degradatory proteins (Grandal et al., 2007).  Stimulation of EGFR by its ligand 
EGF leads to receptor homo- or heterodimerization (Olayioye et al., 2000) 
followed by activation of tyrosine kinase domain of the receptor through trans-
tyrosine phosphorylation.  The activated receptor kinase phosphorylates the 
100 
 
tyrosine residues on the C-terminal tail of the ErbB receptors.  These 
phosphorylated sites allow the binding of proteins with src-homology (SH2) 
domains such as Grb2, shc and Nck that act like adaptor proteins that have 
intracellular docking sites for other proteins such as serine threonine kinases.  
This relays the signaling activating other serine threonine kinases and 
transcription factors (Olayioye et al., 2000).  Thus, signaling from EGFR leads to 
an amplification of several signaling pathways that alter protein function and gene 
transcription conducive for oncogenesis.  The best characterized EGFR 
downstream signaling pathways are the RAS-RAF-MEK-ERK and PI3K-AKT 
pathways.   
 
Accumulating evidence suggests a correlation between elevated 
expression of MMPs and glioma progression.  Published findings show that 
MMP-1 (McCready et al., 2005; Stojic et al., 2008), MMP-2 (Gondi et al., 2009), 
MMP-7 (Vince et al., 1999), MMP-9 (Ezhilarasan et al, 2009; Lakka et al., 2002), 
MMP-14, MMP-15 (Fillmore et al., 2001; Zhang et al., 2005) and MMP-16 (Xia 
et al., 2009) are involved in brain tumor biology.  Of the matrix metalloproteinase 
family, MMP-2, MMP-14 and MMP-9 have been the most extensively studied in 
brain tumors whereas MMP-1 is less well-characterized.  We have reported that 
there is a significant increase in MMP-1 mRNA levels in tumor samples from 
patients with GBM relative to normal brain (McCready et al., 2005).  MMP-1, 
which is not typically expressed in normal brain, has been shown to be elevated in 
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gliomas (Hodgson et al., 2009) and correlates with tumor grade and survival time 
(Stojic et al., 2008).  
 
We wanted to examine if amplified EGFR signaling contributes to pro-
invasive MMP-1 protein up-regulation and determine if MMP-1 mediated activity 
is an important contributor to GBM invasion.  Herein, we report that MMP-1 is 
regulated by EGFR.  High expression of MMP-1 is observed after treatment with 
EGF, and this is dependent on EGFR-driven downstream MAPK signaling.  
Inhibition of EGFR using the pharmaceutical inhibitor, AG1478 led to the 
suppression of the EGF induced MMP-1 protein levels.  In addition adenoviral 
mediated transfection of vectors that express dominant negative forms of MEK 
and EGFR led to the inhibition of EGF induced MMP-1 while cells transfected 
with adenoviral CA-MEK led to increased MMP-1.  Functionally EGF induced 
MMP-1 expression correlated with an increase in cellular invasion and treatment 
with AG1478 abrogated this increase.  Although not to the same extent, MMP-1 
siRNA treated cells also blunted the EGF induced invasion. 
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Data are expressed as the mean and SEM of at least three independent 
experiments.  Statistical analysis was done using an unpaired Student's t test. P < 
0.05 was considered significant.  
 
3.3 Materials and Methods   
 
Cell Culture   
Human GBM cell lines (T98G and U87MG) were obtained from American Type 
Culture Collection (ATCC, Manassas, VA, USA) and maintained in Dulbecco‟s 
Modified Eagle Medium (DMEM Invitrogen, Carlsbad, CA, USA) supplemented 
with 4.5 g/l D-glucose, 1% penicillin/streptomycin (Invitrogen) and 10% Fetal 
Bovine Serum (FBS) (Gemini Bio-Products, West Sacramento, CA, USA).  Cells 
were incubated in a humidified incubator at 37°C with 5% CO2 in Nunclon 75cm
2
 
culture flasks (Nunc, Germany) and harvested with 0.25% Tryspin-EDTA 
(Invitrogen).  The cells were plated in six-well plates at the density of 200,000 
cells/ml for 24h and then pre- treated with inhibitors AG1478 (300nM) and 
PD184352 (500 nM) (Calbiochem, USA) for 1 hour before adding 20ng/ml EGF 
(Cell signaling, USA).   
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Immunoblot 
 Cell lysates and conditioned media were collected from the GBM cell lines-
T98G and U87MG.  Prior to extraction of conditioned media and cell lysates, 
complete serum media was aspirated from six-well plates well and washed with 
PBS.  One ml serum –free media was added to each well and incubated for 24h.  
Then the conditioned media was aspirated and centrifuged at 1000 X g to remove 
cell debris.  The supernatant was collected and added to Amicon centrifugal filters 
(Millipore) for concentration of the protein from 3ml to 250 μl.  For preparation 
of cell lysates, the cells were treated with ice cold RIPA buffer (150 mM NaCl, 
50mM Tris, 1% NP-40, 0.5% Sodium Deoxycholate, 0.1% SDS) supplemented 
with protease inhibitors (Calbiochem).  The lysates were centrifuged at 14000 
rpm for 20 min after shearing with 26 gauge needles.  Protein concentrations were 
determined using DC Protein Assay (Bio-Rad, Hercules, CA, USA)  
 
MMP-1 protein level was determined by immunoblot analysis.  Proteins isolated 
from conditioned media (10ug) and cell lysates (30μg) were separated in 4-12% 
polyacrylamide –bis-Tris gels (Invitrogen, Carlsbad, USA) and transferred to a 
0.45μm nitrocellulose membrane (Invitrogen, Carlsbad, USA).  After blocking in 
5% milk in TBST (50mM Tris base, 150mM NaCl, 0.05% (v/v) Tween 20), the 
membranes were incubated with mouse monoclonal anti-MMP-1 antibody (R & 
D Systems, Minneapolis, MN, USA at 1:200 dilution) in the blocking solution.  
Rabbit polyclonal anti-cyclophilin A antibody (Millipore, Billerica, MA, USA) 
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was used to quantify any variability in loading onto the polyacrylamide gels.  
After washing the membranes in TBST, they were incubated with horseradish 
peroxidase –conjugated secondary antibodies: goat anti rabbit IgG and goat anti 
mouse IgG, (Rockland Immunochemicals, Gilbertsville PA, USA) both diluted 
1:5000 in 5% milk-TBST solution.  Blots were visualized with exposure of 
autoradiographic film using an enhanced chemiluminescent system (ECL, GE 
Healthcare).  The developed films were scanned and densitometry was performed 
using ImageJ.   
 
Adenoviral Transfections 
 T98G cells were plated in six-well plates at a density of 200,000 cells per ml in 
triplicates per condition.  The adenovirus-pCMV, CA-AKT, DN-AKT, CA-MEK, 
DN-MEK (Vector Biolabs, PA, USA) and DN-EGFR (Molecular Biology Core 
Facility, VCU) were a kind gift from Dr Paul Dent, Virginia Commonwealth 
University.  The CA-AKT has myristoylation signal for membrane targeting and 
increased activity.  The DN-AKT has alanine residues substituted for threonine at 
position 308 and serine at position 473.  The CA-MEK has serine 221 alanine 
mutation in MAPK kinase and DN-MEK has serine 217/221 glutamine mutation 
in MAPK kinase.  The DN-EGFR lacks 533 C-terminal amino acids as described 
[21].  The cells were infected with these recombinant adenoviruses at an MOI of 
25 for 48 hours.  Then the media was aspirated and replaced with serum-free 
media for overnight before immunoblotting.  
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MMP-1 siRNA transient transfection  
T98G cells were transfected with Silencer pre-designed siRNAs against MMP-1: 
siRNA ID 1157 sense, GGUAUGAUGAAUAUAAACGtt (Ambion, Austin, TX, 
USA), targeting between 1265 to 1285 bases in the human MMP-1 transcript.  
The cells were plated in complete media (without antibiotics) in six-well plates at 
a density of 200,000 cells per well.  At 80% confluence, media were removed 
from the cells and the wells were washed with PBS followed by addition of 800 
μl per well of Opti-MEM I reduced serum medium (Invitrogen).  Oligofectamine 
transfection reagent, Opti-MEM I and siRNA or scrambled RNA (at 
concentrations of 30nM) mixtures were made and incubated at room temperature 
for 20 min.  Then cells were treated with reaction mixtures of scrambled siRNA 
and predesigned siRNA against MMP-1.  The six well plates were kept on a 
shaker at 37°C for 6 hours.  Opti-MEM I supplemented with 30% FBS was added 
(500 μl per well) for overnight incubation.  Complete media were added the next 
day (500μl per well).  At the end of 48 hours, media were replaced with serum-
free media for overnight incubation at 37°C.  Proteins were extracted from 
conditioned media and cells after the overnight incubation.   
 
Matrigel Invasion Assays 
 Invasiveness of GBM cell lines was determined using transwell inserts (Corning 
Incorporated, USA) with 8μm pores.  The inserts were coated with growth factor 
reduced Matrigel (BD Biosciences, CA, USA) at a concentration of 100μg per 
106 
 
filter diluted in cold serum-free DMEM for 30 minutes at 37°C incubator.  600 μl 
of 10% serum containing medium was added to the bottom chamber.  The cells at 
a density of 1x10
6 
cells per ml were added to the top chamber and incubated at 
37°C for 48 hours.  At the end of incubation, media from bottom chamber was 
removed and trypsin-EDTA was added.  The cells from bottom of the filter were 
scraped and added to trypsinized cells.  The cell number was assessed CellTiter-
Glo luminescent Cell Viability ATP assay (Promega). A standard curve of known 
ATP concentrations was generated for each assay.  The measurement of number 
of cells was correlated with the luminescence obtained from serial dilutions of 
cell-counts from T98G cell line.  Percent invasion was calculated as the 
(luminescence values obtained from analyzing the cells that invaded the matrigel) 
divided by the (luminescence obtained from cell-count added to the top well) X 
100.  Data from three separate experiments with five replicates for each condition 
were analyzed.  
 
Statistical Analysis   
Data were evaluated by comparing the means and SEM of replicate experiments.  
Data are expressed as the mean and SEM of at least three independent 
experiments.  Statistical analysis was done using an unpaired Student's t test. P < 
0.05 was considered significant. 
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Data are expressed as the mean and SEM of at least three independent 
experiments.  Statistical analysis was done using an unpaired Student's t test. P < 
0.05 was considered significant.  
 
3.4 Results  
EGFR mediates regulation of MMP-1  
 T98G and U87MG glioma cell lines were examined for changes in the 
expression of MMP-1 protein following EGF treatment.  Addition of 20 ng/ml 
EGF led to phosphorylation and activation of EGFR within 2 minutes and the 
phosphorylation status was sustained over 15 min and 24 hour time points 
(Figure 3.1A).  MMP-1 protein levels were analyzed in T98G and U87MG 
glioma cell lysates and conditioned media 24 hours following EGF treatment.  
MMP-1 levels were increased several fold in both cell lines (T98CL = 9 fold, p 
<0.05 T98CM= 0.75 fold, p< 0.05 U87CL= 3 fold, p<0.05 U87CM= 6.5fold, 
p<0.05) (Figure 3.1B, 1C).  We next sought to inhibit the activation of EGFR 
using the small molecule inhibitor, AG1478 in T98G cells.  Addition of AG1478 
(300 nM) 2h prior to treatment with EGF completely inhibited the activation of 
EGFR by EGF (Figure 3.1D).  MMP-1 protein levels were also decreased in 
samples treated with AG1478 alone.  These findings demonstrate that EGFR 
activation by EGF specifically regulates the expression of MMP-1.  
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Figure 3.1 Regulation of MMP-1 by EGF  Representative immunoblots 
of T98G and U87MG glioma cell lysates (CL) from A) cells treated with EGF (20 
ng/ml) for 2, 10 and 15 min show activation of EGFR, B) cells treated with EGF 
(20 ng/ml) for 24h demonstrate induction of MMP-1 in CL and conditioned media 
(CM).  C)  Densitometric analysis of MMP-1 protein band intensity across three 
independent experiments, p
*
<0.005 (n=3). D) Cells treated with AG1478 
(300nM) for 24h show complete inhibition of EGFR activation and MMP-1 
protein levels in T98G CL, Densitometric analysis across three independent 
experiments, p*<0.05 (n=3). 
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Involvement of MAPK pathway in the EGF mediated induction of 
MMP-1  
 
To determine downstream EGFR signaling pathways involved in the 
increase in MMP-1 expression, T98G cells were first treated with selective 
MEK1/2 inhibitors U0126 and PD184352.  Pre-treatment with 500nM PD184352 
for 2 hours before addition of EGF completely inhibited the phosphorylation of 
ERK (Figure 3.2A, lanes 5 and 6).  EGF treatment had no effect on 
phosphorylated or total ERK1/2 levels in this cell line (Figure 3.2A, lanes 2 and 
4).  MMP-1 levels were also examined in T98G cells treated with PD184352 for 
24 hours.  There was a suppression of MMP-1 induction in the presence of EGF 
in the cells treated with PD184352 (Figure 3.2A lanes 5 and 6) suggesting 
MMP-1 regulation is effected by the MAPK pathway. 
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Figure 3.2 Inhibition of MAPK signaling by PD184352 and MMP-1 levels.   
A) Representative immunoblot of T98G CL, from cells treated with PD184352 
(500nM) for 24h indicating complete inhibition of ERK activation and decreased 
induction of MMP-1 protein levels in the presence of EGF (CL, cell lysate; ERK, 
p44/42 Erk1/2 Mitogen activated kinases).  B) densitometric analysis of MMP-1 band 
intensity across three separate experiments, p
*, **
<0.05 [*, DMSO (-EGF) Vs 
PD184352 (-EGF)], [**, DMSO (+EGF) Vs PD184352 (+EGF)] (n=3). 
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Involvement of MAPK pathway in the EGF mediated induction of 
MMP-1  
 
To examine more closely the possible involvement of the MAPK signaling 
pathway in EGF-induction of MMP-1, we used adenoviral constructs targeting 
MEK and EGFR.  Constitutively active (CA) and dominant negative (DN)-MEK 
and DN-EGFR –adenoviral constructs were transfected in T98G cells and levels 
of phospho-ERK1/2- and total ERK1/2 and MMP-1 were examined (Figure 3.3).  
The T98G cells transfected with DN-EGFR show decreased levels of p-ERK and 
MMP-1 as compared to pCMV controls (Figure 3.3A lanes 1 and 4).  In the 
presence of DN-MEK, p-ERK and MMP-1 levels were reduced (Figure3. 3A 
lane 3).  Conversely CA-MEK increases MMP-1 protein amounts, with a slight 
increase in the endogenous levels of p-ERK (Figure 3.3A, lanes 1 and 2).  The 
DN-MEK and DN-EGFR completely inhibit phosphorylation of ERK suggesting 
MAPK as an integral component of EGFR downstream signaling. 
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Figure 3.3 EGFR mediated MAPK signaling influences MMP-1 levels.   
A) Representative immunoblot of T98G cells transfected with adenoviral vectors 
CA-MEK, DN-MEK and DN-EGFR (MOI of 25) show complete inhibition of 
ERK phosphorylation in cells treated with DN-MEK and DN-EGFR.  MMP-1 
levels are also decreased in these cell lines.  B) Densitometric analysis across 
three independent experiments showing fold change values of MMP-1 protein 
levels relative to the pCMV control.  The CA-MEK resulted in an approximately 
3 fold increase in MMP-1 protein levels whereas transfection of DN-MEK 
decreased MMP-1 levels to 0.3 fold and that of DN-EGFR decreased MMP-1 
levels to 0.2 fold relative to the pCMV control (CA-Constitutive active, DN-
Dominant negative).  Data is representative of three separate experiments, p 
*, **, 
***
 <0.05 (n=3). 
 
 
 
 
 
 
 
 
117 
 
 
 
 
 
 
 
 
 
 
118 
 
 
Role of PI3-kinase pathway in EGF mediated MMP-1 regulation  
 
We also wanted to examine the PI3 Kinase pathway and its potential influence on 
EGF-induced MMP-1 expression.  T98G cells were pre treated with two 
concentrations of AG1478 (10nM and 30nM) for 2 hours and stimulated with 
EGF (20ng/ml).  The activation status of EGFR, AKT and ERK was tested in 
these treated samples.  In the presence of EGF, p-EGFR was inhibited by AG1478 
(Figure 3.4A lanes 1, 3 and 5).  In agreement with Figure 2, EGF had no effect 
on the p-ERK levels.  There was a dose-dependent inhibition of EGF stimulated 
p-Akt levels with increasing amounts of AG1478 (Figure 3.4A, lanes 1, 3, and 
5).  In addition, basal and EGF-stimulated p-ERK levels were unchanged and the 
AG1478 treatment did not affect the phosphorylation status of ERK (Figure 
3.4B).  These observations suggest that in addition to the MAPK pathway, EGF-
induction of MMP-1 may involve the PI3K pathway.   
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Figure 3.4 AG1478 mediates its downstream effects via PI3-K 
signaling   A) Representative immunoblot of T98G cells treated with two 
different concentrations of AG1478 (10 and 30 nM) show decreased levels of p-
EGFR and p-AKT but no effect on p-ERK.  B) Densitometric analysis of EGFR, 
AKT and ERK (phospho- and total)  immunoreactivity in the above immunoblots 
across three separate experiments, p*<0.05 
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Role of PI3-kinase pathway in EGF mediated MMP-1 regulation 
To further examine the role of PI3K in EGF induced MMP-1 expression, 
adenoviral constructs (CA-AKT and DN-AKT) were used to transfect T98G cells.  
Successful adenoviral transfection was confirmed by immunoblotting to detect 
phospho-Serine 473-AKT and total-AKT (Figure 3.5A).  Only the CA-AKT 
treated T98G cells were shown to have high Serine-473 phosphorylation levels 
(Figure 3.5A, lane 2).  Surprisingly, the MMP-1 levels remain same in T98G 
cells transfected with adenoviral- CA-AKT and DN-AKT plasmids and are 
similar to the pCMV controls (Figure 3.5A, lanes 1 to 3). Consistent with earlier 
data (Figure 3.3A lanes 1 and 4, 3.3B) T98 cells treated with adenoviral DN-
EGFR plasmids demonstrate a decrease in MMP-1 levels to 0.3 fold as compared 
to the pCMVcontrol (Figure 3.5A, lanes 1 and 4, Figure 3.5B). 
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Figure 3.5 PI3-K signaling does not influence MMP-1 levels  A) 
Representative immunolot of T98G cells treated with adenoviral vectors CA-AKT 
and DN-AKT (MOI of 25) show that CA-AKT led to phosphorylation of AKT at 
473 position with no active AKT in the control samples. This increased 
phosphorylation did not lead to alterations in MMP-1 levels.  B) Densitometric 
analysis of the MMP-1 immunoblots across three separate experiments showing 
fold change values relative to the pCMV control.  The DN-EGFR sample group 
shows a decrease in MMP-1 levels to approx 0.3 fold as compared to the pCMV 
control group.  Data is representative of three independent experiments, p*<0.05, 
n=3. 
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EGF stimulates glioma cels invasion in vitro  
 
We next wanted to examine whether MMP-1 upregulation by EGF is an important 
event in the in vitro invasion process in glioma cells.  T98G cells were treated 
with DMSO and AG1478 in the presence and absence of EGF.  Inhibition of 
MMP-1 was performed using transient transfection of MMP-1 siRNA.  Treatment 
with AG1478 alone in T98G cells significantly decreased invasion as compared to 
the DMSO control.  Similarly, MMP-1 siRNA treatment to T98G cells 
significantly suppressed invasion as compared to the scrambled control (p < 0.05) 
(Figure 3.6).  The addition of EGF to T98G cells (No treatment, NT and DMSO-
treated) led to an increase in invasion (p<0.05).  The addition of EGF to AG1478 
treated T98G cells did not increase invasion suggesting suppression of EGFR-
mediated pro-invasive signaling.  Interestingly, addition of EGF to MMP-1 
siRNA treated T98G cells resulted in an increase in invasion but this increase was 
not as pronounced as controls.  This data suggests that MMP-1 inhibition results 
in blunting the EGF-mediated increase in invasion and therefore contributes, in 
part, to EGF-mediated invasion process. 
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Figure 3.6 EGFR mediated increased invasion involves MMP-1 in 
T98G cells. Representative immunoblot of T98G cells treated with controls (NT, 
DMSO), AG1478, scrambled control, MMP-1 siRNA (with and without EGF) 
show that MMP-1 levels are decreased in AG1478 and MMP-1 siRNA treated 
cell lysates even in the presence of EGF. EGF stimulation induced MMP-1 
protein levels in controls (NT, DMSO and scrambled).  B) Addition of EGF to 
T98G cells in controls (NT, DMSO and scrambled) led to a significant increase in 
matrigel-invasion.  In the presence of AG1478, the EGF mediated increased 
invasion is inhibited. MMP-1 siRNA treated T98G cells show decreased invasion 
as compared to the controls.  In MMP-1 siRNA treated T98G cells, an increase in 
invasion was observed with addition of EGF.  However, the induction of invasion 
by EGF was suppressed in these MMP-1 siRNA treated cells as compared to the 
induction of invasion in NT, DMSO and scrambled sample groups.  Data is 
representative of three independent experiments, p*<0.05, p
#
(Scrambled Vs 
MMP-1 siRNA) <0.05, p
**
(AG1478 Vs DMSO, No EGF) <0.05, p
##
(AG1478 Vs 
DMSO, with EGF) <0.05 (n=3). 
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3.5 Discussion 
 
EGFR expression and mutation is an important hallmark event in many cancers, 
including glioblastoma (GBM).  Particularly, primary GBMs, also known as de-
novo GBM have been found to have a higher EGFR mutation rate than 
progressive or secondary GBM (Ohgaki and Kleihues, 2007), and is recognized to 
be a significant oncogene driving the growth and malignancy these cancers.  
There is evidence for the involvement of MMP-1 in local diffuse invasion in 
GBM (Stojic et al., 2008; McCready et al., 2005; Anand M et al, submitted).   
 
In this study, we sought to examine the role of EGFR signaling in the EGF 
induction of MMP-1.  We observed that by perturbing EGFR using EGF 
stimulation in 2 glioma cell lines, MMP-1 expression was increased.  In the same 
model system, inhibition by AG1478 and EGFR- dominant negative forms, levels 
of MMP-1 are altered.  Subsequently, we explored EGFR downstream MAPK 
and PI3-K signaling mechanisms.  Using a pharmaceutical inhibitor for the 
MAPK pathway, PD184352, we observed an abrogation in the induction of 
MMP-1 protein levels in samples treated with the inhibitor and EGF.  Neither the 
addition of EGF nor adenoviral mediated-infection of MEK-CA in T98G cells 
increased the phosphorylation of ERK above the basal levels of p-ERK.  
However, the transfection of Ad-EGFR-DN in T98G cells led to the suppression 
of phosphorylated ERK and abrogated MMP-1 levels suggesting EGFR-mediated 
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MAPK regulation of MMP-1.  In T98G cells infected with an adenoviral-
construct MEK-DN, MMP-1 levels were abolished.  In addition, infection of 
T98G cells with adenoviral-MEK-CA led to a robust increase in the MMP-1 
protein levels strongly suggesting involvement of MAPK pathway in MMP-1 
gene regulation.  
 
AG1478 treatment led to the suppression of p-EGFR and p-AKT levels 
but did not alter p-ERK levels.  It also resulted in decreased MMP-1 levels 
suggesting that PI3K signaling might also be involved in the EGF-MMP-1 
regulation.  There was an apparent dose-dependent decrease in phosphorlyated 
EGFR with AG1478 treatment.   In figure 3.4 we show that with two doses of 
AG1478 (10 and 30nM) there is a modest dose dependent decrease in 
phosphorylated EGFR.  The addition of higher doses of AG1478 (100 and 300 
nM) completely inhibited phosphorylation of EGFR (data not shown).    
 
We further explored the PI3-K signaling pathway by infecting T98G cells 
with Ad-AKT-CA and Ad-AKT-DN.  Interestingly, neither Ad-AKT-CA nor Ad-
AKT-DN transfection in T98G cells altered MMP-1 levels suggesting that PI3K 
may not involved in the EGF-induction of MMP-1 protein.    
 
MMP-1 has pro-invasive functions in wide range of malignancies.  In 
order to examine, if EGFR mediated increase in MMP-1 plays a functional role in 
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T98 cells, we performed invasion assays.  There was a significant increase in 
invasion with EGF treatment and with AG1478 treatment this EGF-driven 
invasion nis abolished.  The MMP-1 siRNA demonstrated a similar effect.  When 
EGF was added to the MMP-1 siRNA treated cells, although not to the same 
extent as with AG1478, there was a suppression of the EGF-driven invasion.  
Thus, MMP-1 inhibition is able to blunt the EGF-mediated increase in invasion in 
T98G cells emphasizing an important contribution to glioma cell in vitro invasion 
by MMP-1. 
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CHAPTER-4 
 
 
GENERAL DISCUSSION 
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In this study, we have shown that MMP-1 is a significant contributor of glioma 
invasion in vitro.  Preliminary studies from our laboratory by Dr Jessica 
McCready showed that MMP-1 mRNA is not detectable in normal brain but its 
expression is increased in GBM tissue specimens.  The MMP-1 protein levels in 
GBM tissue specimens were examined using immunohistochemistry and 
confirmed these earlier results.  T98G cell lines were used for transient inhibition 
of MMP-1 as they have high basal expression of MMP-1.  Conversely, the 
U251MG and U87MG cell lines have low basal expression of MMP-1 making 
them a suitable model for over-expression studies.  Inhibition of MMP-1 using 
siRNA in T98G cell lines showed a decreased invasion while stable over-
expression of MMP-1 in U251MG and U87MG GBM cell lines exhibited 
significantly increased invasion.  These MMP-1 over-expressers have the ability 
to invade growth factor- reduced matrigel barrier (at 100 μg/ filter concentration) 
within 12 hours as observed under the microscope.   
 
Several MMPs have been implicated in brain tumors; among them, the 
most extensively studied are MMP-2 and MMP-9 (Kargiotis et al., 2008; Gondi et 
al., 2009; Ezhilarasan et al., 2009; Lakka et al., 2002, 2005).  The studies 
presented in this dissertation focused on the functional role of MMP-1 in GBM, 
particularly invasion.  MMP-1 contributes to invasion and metastasis in various 
malignancies including breast, colon, ovary, skin and pancreas (Murray et al., 
1996; Kanamori et al., 1999; Ito et al., 1999; Brinckerhoff et al., 2000; Behrens et 
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al., 2001; Ghilardi et al., 2001; Wyatt et al., 2005; Nikkola et al., 2005; Ala-aho et 
al., 2005).  In most of these cancers, MMP-1 favors tumor progression, growth 
and invasion by its traditional function of degradation of rigid constituents of 
ECM.  However, brain ECM is devoid of such rigid barriers and it composed of 
loosely bound hyaluronan, proteoglycans, tenascin-C and thrombospondin.  
Nonetheless, collagen types IV, V, fibronectin and laminin are present in low 
amounts along the vessel walls alongside basement membrane and peri-vascular 
matrix (Bellon et al., 1985).  Brain tumors rarely metastasize outside the brain and 
there is no intravasation in GBM (Bellail et al., 2004).  The GBM cells show a 
pattern of infiltration along the periphery of vessel walls and white matter along 
with widespread movement within the brain.  It is important to note here that 
despite the presence of very low quantities of known MMP-1 substrates around 
peri-vascular region, over-expression of MMP-1 increases invasion significantly.  
It is therefore possible that the increased invasion mediated by over-expression of 
MMP-1 is not solely due to degradation of ECM.  The above findings compelled 
us to consider additional functions of MMP-1 in ECM dynamics.   
 
MMP-1 alters invasion in GBM by cleaving biologically active molecules 
We considered two substrates of MMP-1 that have been shown to be activated: 
IGFBP2/3 and PAR-1.  MMPs function in conjunction with each other and non-
traditional substrates for MMPs are continuously being identified.  MMP-1 
cleaves various bio-active molecules present in the ECM to up-regulate oncogenic 
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signaling (Sternlicht and Werb, 2001; Brinckerhoff et al., 2002).  Literature 
review lends evidence that insulin-growth factor binding proteins (IGFBPs) 
present in ECM are cleaved by MMP-1 and MMP-3 (Fowlkes et al., 1994; Rajah 
et al., 1999).  IGFBPs are highly over-expressed and correlate with increased 
invasion in GBM (Zhang et al., 2002).  Silencing of IGFBP-2 in human GBM 
cells reduced invasion (Fukushima et al., 2007) and its over-expression promotes 
glioma development and progression (Dunlap et al., 2007).  Because of this 
correlation between MMPs and IGFBPs, we examined the affect of active and 
functional MMP-1 on IGFBPs (Appendix E).  In summary, our preliminary in 
vitro data suggests that MMP-1 does not cleave IGFBPs in T98G cells.   
 
Recent studies have shown that MMP-1 directly cleaves a G-protein 
coupled receptor (GPCR), Protease-activated Receptor (PAR-1), which is also a 
pro-angiogenic molecule (Boire et al., 2006; Blackburn et al., 2009).  Cleavage of 
PAR-1 leads to activation of downstream G-protein couple signaling that aids in 
the invasion, metastasis, growth, proliferation and aggressiveness of several 
malignancies (Granovsky-Grisaru et al., 2006; Salah et al, 2007; Agarwal et al 
2008).  PAR-1 is expressed extensively in human brain on neurons and astrocytes.  
Activation of PAR-1 in both astrocytes and human GBM cell lines (U178) 
increases the intracellular calcium ion concentration suggesting it is equally 
functionally active in normal and pathological states of brain (Junge et al., 2004).   
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We tested the presence of PAR-1 in T98G, U251MG and U87MG GBM 
cell lines via western blot analaysis but were unable to detect PAR-1.  This could 
be due to the low or nil expression of PAR-1 in in vitro conditions in these cell 
lines and a more sensitive method such as ELISA is needed to detect the receptor.  
It would be interesting to examine the PAR-1 cleavage and activation of 
downstream GPCR signaling in the U251MG cells stably over-expressing MMP-
1.  The high levels of MMP-1 protein expressed by U251-MMP-1OE clones 
should be activated to achieve a functional and active form of MMP-1.  This can 
be obtained by treating the conditioned media from these cells with APMA 
followed by dialysis for removal of the organo-mercurial compound.  The 
resulting conditioned media can be used to treat the cells for examining the PAR-
1 cleavage.  The PAR- cleavage can be determined by measuring the PAR-1 
cleaved fragment using ELISA and intracellular concentration of calcium ions.   
 
The in-vitro invasion assays performed with MMP-1 over-expressing 
U251MG and U87MG cell lines showed an increase in invasion without altering 
the cell-proliferation rate.  In the same lines, siRNA inhibition of MMP-1 in 
T98G cell lines showed a decreased invasion without affecting the cell viability 
and proliferation rate as measured by cell proliferation assays.  Thus, MMP-1 may 
affect on the cell morphology which changes during the physical movement of the 
cell.  In experiments where recombinant active MMP-1 was added to the cells 
during the invasion assay, we observe no difference in invasion as compared to 
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the controls.  Based on these findings, one would also believe that MMP-1 is not 
affecting the growth or proliferation of the cells in-vitro.  However, in a parallel 
in-vivo study performed by my colleague, Dr Nicholas A Pullen, we observed that 
these MMP-1 over-expressing U251MG cell lines show significant increase in 
tumor growth and volume.  Moreover, the T98G GBM cell lines stably 
transfected with lentiviral MMP-1 shRNA show a stark decrease in tumor volume 
(Pullen et al., 2010–submitted).  These results emphasize the importance of the 
tumor microenvironment and its role in mediating the effects of MMP-1.   
 
A majority of GBM patients have amplification, over-expression and/ or 
mutation in the EGFR making this particular receptor an attractive target for 
therapeutics.  EGFR is known to up-regulate various oncogenes that are 
implicated in cell proliferation, invasion, metastasis and tumor growth.   
 
In this study we demonstrated the induction of MMP-1 by EGF.  EGF, at 
concentration of 20ng/ml for 24h show an induction of MMP-1 in T98G and 
U87MG cell lines.  Using a pharmaceutic inhibitor of EGFR, AG1478 at a dose of 
300 nM, we observed a complete inhibition of EGFR activation.  After the 
treatment with AG1478 (300 nM) in T98G cell lines for 24 hour time period, we 
observed that MMP-1 levels are completely abolished in the AG1478 treated 
samples as compared to the controls.  This data confirms that EGFR is playing an 
important role in the regulation of MMP-1 expression.   
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To understand the downstream signaling mechanisms that are mediating 
the EGF-MMP-1 regulation, we used pharmaceutic inhibitors to two of the most 
important and extensively studied pathways- MAPK and PI3-K/AKT.  For 
MAPK inhibition, we used the U0126 inhibitor at a dose of 30 μM.  Inhibition of 
PI3K-AKT pathway was performed using LY294002 (5 μM).  We observed that 
with U0126, phosphorylation of ERK (p-ERK) is inhibited and over a 24 hour 
time period, the MMP-1 levels are also abrogated.  These experiments were 
performed in the presence and absence of EGF (20 ng/ml).  We also notice that 
addition of EGF did not increase p-ERK levels above the existing high basal 
levels.  Treatment of T98G cells with LY294002 did not prove to be conclusive 
because the cells did not survive at the period of 24 h.  A dose dependent 
inhibition experiment was performed using the drug that shows complete 
inhibition of p-AKT starting at 5 μM and almost complete inhibition at 10 μM.  
Nonetheless, the cells did not tolerate lower doses of the drug over a 24 h time 
period.  To perform MAPK inhibition at a more physiologically relevant dose, we 
also used another inhibitor, PD184352 at 500 nM.  This inhibitor treatment 
resulted in same results as U0126 lending credence to the involvement of MAPK 
in MMP-1 regulation.   
 
An important observation was made in T98G cells treated with both 
agonist (EGF) and antagonist (AG1478) of EGFR.  In these cells, EGF led to an 
activation of EGFR and AKT.  Inhibition of EGFR receptor activation also 
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resulted in decreased p-AKT levels.  However, the levels of p-ERK were entirely 
unaffected with EGF and AG1478.  At a 10 nM dose of AG1478, the extent of 
inhibition on AKT is more pronounced than on its primary target, EGFR.  This 
may suggest that AKT pathway could be very sensitive to inhibition of EGFR; a 
small inhibition in the receptor results in a marked decrease in the activation of 
AKT.   
 
A more specific approach to inhibit the signaling pathways was adopted 
using adenoviral vectors that target the effector proteins of the pathways.  These 
adenoviral vectors were a kind gift from Dr Paul Dent laboratory, Department of 
Biochemistry, Virginia Commonwealth University.  The recombinant adenoviral 
vectors were EGFR-dominant negative (DN), AKT-constitutive active (CA), 
AKT-DN, MEK-CA and MEK-DN.  We observed that infection with Ad-EGFR-
DN decreased the MMP-1 protein levels substantiating our earlier results with the 
pharmaceutic inhibitor, AG1478.  Ad-MEK-DN remarkably decreased the MMP-
1 levels and also inhibited the activation of ERK.  Surprisingly, Ad-EGFR-DN 
also resulted in the inhibition of ERK activation suggesting MAPK is indeed 
downstream to EGFR signaling.  Ad-AKT-CA infection show increased 
phosphorylation and activation of AKT at position serine -473.  However, there 
was no change in the levels of MMP-1 with Ad-AKT-CA and Ad-AKT-DN.  This 
data strongly highlights the involvement of MAPK pathway in EGFR mediated 
regulation of MMP-1.   
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The fact that we could not detect a change in p-ERK levels following 
addition of EGF could be due to high basal p-ERK expression in T98 cells. .  The 
increase in p-ERK levels with EGF may not be detectable over this high-basal 
level.  With addition of adenoviral dominant negative-EGFR, we observe 
complete inhibition of the ERK phosphorylation, however this inhibition was not 
observed with AG1478, a pharmaceutic inhibitor.  AG1478 is a reversible 
inhibitor that binds to the ATP-binding pocket of the activated receptor.  Our 
earlier results with AG1478 pointed to inhibition of AKT at much lower doses 
than it inhibits its specific receptor, EGFR.  This suggests that AKT pathway is 
more sensitive to AG1478 treatment whereas inhibition of MAPK pathway 
requires more permanent and robust approach, more so, as the basal levels of 
pERK are high.   
 
We found that in Ad-MEK-CA transfections, there is a slight increase in 
the phosphorylation of ERK.  We had expected a more robust increase of pERK 
due to the large increase in MMP-1 exprssion.   There is a possibility of cross-talk 
mechanisms between MEK1/2 and JNK.  Published findings hint that ERK may 
not the only target for MEK1/2 (Adler et al., 2005).  In U251 GBM cell lines, 
hyperphosphorylated MEK1/2 can phosphorylate JNK which further activates p38 
MAPKs (Adler et al., 2005).  These proteins increase the pool of AP-1 
transcription factors in the cell and can lead to increases in MMP-1 transcription.   
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We also explored the role of another important signaling pathway 
downstream to EGFR in the regulation of MMP-1- the JAK/STAT pathway.  In 
T24 bladder cancer cells, STAT3 activation was found to be important and 
necessary for MMP-1 induction by EGFR (Itoh et al., 2006).  We wanted to 
determine if such a mechanism may also be part of GBM cells.  To investigate the 
role of JAK/STAT pathway, we used siRNA against STAT3 in T98G cell lines 
and examined MMP-1 levels (Appendix F).   
 
We had expected that STAT3 siRNA would decrease the levels of MMP-
1.  But, we observed completely contrary to what we had anticipated.  The 
STAT3 siRNA treated T98G cells show an induction of MMP-1 as compared to 
the scrambled and transfection regeant control.  To determine if other signaling 
pathways become activated in the event of STAT3 depletion as a compensatory 
mechanism, we examined the MAPK pathway activation by analyzing p-ERK 
levels.  We observed that pERK levels did not change in the STAT3 siRNA T98G 
cell lines.  In the absence of any stimulatory signal (such as EGF), we could not 
detect and discern any differences in pAKT levels, although the total AKT levels 
remain constant.   Recent studies show that STAT3 has a tumor suppressive 
function in the GBM cells.  Interleukin-8 (IL-8) is a direct repressed target gene 
for STAT3 (de la Iglesia et al., 2008).  This repression is released during siRNA 
inhibition of STAT3 thereby allowing IL-8 to mediate its downstream signaling 
that may up-regulate MMP-1 expression.   
142 
 
We have seen that in GBM cell lines, EGFR is regulating MMP-1 
expression preferentially by the MAPK pathway.  We next sought to determine if 
EGFR mediated increased MMP-1 has a functional role of invasion.  The T98G 
cells were treated with controls, AG1478 and MMP-1 siRNA and allowed to 
invade in a matrigel-based invasion assay in the presence and absence of EGF.  
We show here that MMP-1 siRNA significantly decreased invasion as compared 
to the controls corroborating our earlier data.  In controls, the EGF treatment led 
to a significantly increased invasion but in the presence of AG1478, the cells 
drastically reduced this EGF-mediated increased invasion.  Addition of EGF to 
MMP-1 siRNA treated T98G cells resulted in a blunting of the EGF-driven 
increase in glioma invasion.   MMPs are regarded as main players in the invasion 
process and as such other MMPs may be regulated by EGF and EGFR.  Previous 
published reports by our laboratory (Van Meter et al., 2004) report the induction 
of MT1-MMP by EGF stimulation.   
 
In summary, we have shown that MMP-1 plays a role in GBM invasion in 
vitro.  The increased expression of MMP-1 could be attributed to the complex 
milieu of tumor microenvironment that is teeming with growth factors and 
oncogenic stimuli.  In our studies, we found that EGFR is regulating MMP-1 
expression by MAPK pathway in T98G GBM cell lines.  The finding by others 
that MMP-1 can cleave PAR-1 is an important development in MMP-1 biology.  
One proposed hypothesis is that once activated MMP-1 cleaves PAR-1, not only 
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the GPCR, but other RTKs get activated by transactivation mechanisms.  There 
are unpublished reports that hint that EGFR can be shed by MMPs (personal 
communication).  The activation of EGFR and GPCR signaling pathways up-
regulate various oncogenic and invasive genes including MMP-1 thereby creating 
a feedback loop (Figure 4.1). With the aid of tumor micro-environment, cancer 
cells must maintain such feedlack loop constitutively for survival and growth. 
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Appendix A: 
Cloning strategy for MMP-1   
MMP-1 was purchased in the pOTB7 vector that had been modified with attB sites.  This 
would allow cloning into an entry vector (pDONR221) using the Gateway system by 
Invitrogen.  Once the entry clone is obtained, MMP-1 can be moved into a variety of 
destination vectors using the Invitrogen Gateway cloning system.  The pIRES2Ac-GFP, a 
vector from Clontech, has been converted to a destination vector and was used for this 
project.   
 
MMP-1/pOTB7 and pDONR221 DNA (1:1 molar ratio) was set up in a BP reaction and 
1ul was transformed into electrocompetent α–select cells from Bioline.  The BP reaction 
is mediated by BP clonase enzymes composed of Integrase and Integrase host factor 
(IHF) proteins that facilitate the recombination between DNA clones containing attB sites 
and a donor vector with attP sites.  The cells were plated on kanamycin plates (50ug/ml 
LB agar).  Colonies were analyzed by the Epicenter Colony Fast-Screen Kit 
(Cat#FS0472H).  The correct colony was struck on another kanamycin LB (Luria Broth) 
agar plate and a single colony was used for inoculation of a miniprep culture.  DNA was 
isolated using the Fermentas GeneJet Miniprep Kit (Cat#K0503).  The DNA was 
digested with NsiI enzyme that would disrupt the kanamycin gene of the pDONR221 
backbone.  The DNA was purified using the PCR cleanup procedure of the Promega 
Wizard SV Gel and PCR Cleanup System (Cat#A9282)  
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MMP-1/pDONR221 DNA and pIRES2Ac-GFP/rfa DNA (1:1 molar ratio) 
was set up in an LR reaction and 1µl was transformed into electrocompetent α–
select cells from Bioline.  In an LR reaction, the integrase, IHF and excisionase 
(Xis) enzymes catalyze the recombination between entry clone (carrying gene of 
interest flanked with attL sites) and a destination vector with attR sites.  The cells 
were plated on kanamycin plates (50ug/ml LB agar).  Colonies were analyzed by 
the Epicenter Colony Fast-Screen Kit (Cat#FS0472H).  The correct colony was 
struck on another kanamycin LB agar plate and a single colony was used for 
inoculation of a day culture.  An overnight maxiprep culture was inoculated from 
the day culture.  DNA was isolated using the Invitrogen PureLink HiPure 
Maxiprep Kit (Cat# K210007).  
BP Reaction Creating a Gateway® entry clone from an attB-flanked PCR 
product Add the following components to a 1.5 ml tube at room temperature and 
mix: attB-PCR product (=10 ng/µl; final amount ~15-150 ng) 1-7 µl Donor vector 
(150 ng/µl) 1 µl TE buffer, pH 8.0 to 8 µl 
1. Thaw on ice the BP Clonase™ II enzyme mix for about 2 minutes. Vortex 
the BP Clonase™ II enzyme mix briefly twice (2 seconds each time). 
2. To each sample (Step 1, above), add 2 µl of BP Clonase™ II enzyme mix 
to the reaction and mix well by vortexing briefly twice. Microcentrifuge 
briefly. 
3. Return BP Clonase™ II enzyme mix to -20°C or -80°C storage. 
4. Incubate reactions at 25°C for 1 hour. 
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5. Add 1 µl of the Proteinase K solution to each sample to terminate the 
reaction. Vortex briefly. Incubate samples at 37°C for 10 minutes.  
LR Reaction Transferring the gene from a Gateway® entry clone to 
destination vector   
1. Add the following components to a 1.5 ml tube at room temperature and mix: 
Entry clone (50-150 ng) 1-7 µl 
2. Destination vector (150 ng/µl) 1 µl, TE buffer, pH 8.0 to 8 µl 
3. Thaw on ice the LR Clonase ™ II enzyme mix for about 2 minutes. Vortex the 
LR Clonase ™ II enzyme mix briefly twice (2 seconds each time). 
4. To each sample (Step 1, above), add 2 µl of LR Clonase ™II enzyme mix to the 
reaction and mix well by vortexing briefly twice. Microcentrifuge briefly. 
5. Return LR Clonase ™ II enzyme mix to -20°C or -80°C storage. 
6. Incubate reactions at 25°C for 1 hour. 
7. Add 1 µl of the Proteinase K solution to each sample to terminate the reaction. 
Vortex briefly. Incubate samples at 37°C for 10 minutes. 
 
Cloning and molecular biology procedures were performed at the VCU – Massey 
Cancer Center Molecular Biology Core Facility, supported, in part, with funding 
from NIH-NCI CCSG Center core grant (2-P30-CA-16059) 
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Appendix B: Vector Map of Donor Vector 
 
human MMP1/pDONR221
4746 bp
Kan(R)
MMP1
attL1
attL2
T7 primer
M13 rev erse primer
M13 (-40) forward primer
M13 (-20) forward primer
M13R primer
M13F-20 primer
T7 promoter
rrnB T2 transcription terminator
rrnB T1 transcription terminator
Xho I (4669)
Sac I (3603)
EcoRI (2590 )
EcoRI (2867)
NsiI (535)
NsiI (8 01)
 
 
 
 
 
188 
 
Appendix C: Vector Map of Destination Vector 
 
 
human MMP1/pIRES2Ac-GFP-rfa
7565 bp
MMP1
attB1
attB2
AcGFP1
Kanamycin/Neomycin
IRES
poly A
M13F-20 primer
M13R primer
pCMV
puc ori
Sac I (5287)
Sac I (6422)
Xho I (5280)
Xho I (7488 )
EcoRI (5296)
EcoRI (5409)
EcoRI (568 6)
NsiI (2263)
NsiI (2335)
NsiI (4666)
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Appendix D 
Protocol for activation of MMP-1 by APMA  
All solutions were freshly made on the day of performing the assay.  MMP-1 present in 
the conditioned media samples of U251MG and U87MG GBM cells that were stably 
over-expressed with pIRES-MMP-1-AcGFP were treated with amino-phenyl mercuric 
acid (APMA).  
 A stock solution of 10 mM APMA was prepared by dissolving 35.2 mg of 
APMA in 0.1M sodium hydroxide (NaOH).  Tris-Triton-calcium (TTC) buffer was 
prepared with final concentration of 50mM of Tris-HCL, 1mM of calcium chloride and 
0.05% of Triton-X-100.  20 μl of conditioned media containing pro-MMP-1 from each 
cell line was added to 200 μl of APMA (final concentration 4mM) and 280 μl of TTC 
buffer.  The reaction mix was incubated at 37°C water-bath for 24 hours.   
For immunoblots, the conditioned media was used as it is at the end of incubation 
for MMP-1 analysis.  For treatment in cell cultures, the APMA was removed by dialysis 
using Amicon Ultracentrigufal filter devices.  Before addition of the reaction mix, the 
filters were blocked with 100 μl of 1mg/ml of bovine serum albumin (BSA) for 30 min at 
37°C.  Thereafter, 500 μl of sterile PBS was added and the filters were centrifuged at 
11,000 x g for 20 minutes at 4°C.  The filters were inverted and spun briefly to remove 
residual PBS and then dried.  The reaction mixture was added to these filters and 
centrifuged at 11,000 x g for 20 minutes at 4°C to remove APMA.  This was repeated so 
as to remove the maximal amount of APMA.  The concentration of proteins in 
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conditioned media was then analyzed using Biorad-DC protein assay.  Equal amount of 
protein was used for treatment of cells in culture. 
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Appendix E  
IGFBP2/3 does not get cleaved in the presence of activated MMP-1 from U251MG 
MMP-1 overexpressing cells.  
 
In the above figure, conditioned media from U251MG cells (Parentals P, Vector control 
VC, MMP-1 over-expressers MMP-1 OE) was extracted and concentrated.  MMP-1 was 
activated using APMA and levels of IGFBP2/3 were examined.  The data shows that 
MMP-1 gets activated with APMA treatment.  There is no affect on IGFBP-2/3 by 
activated MMP-1.  APMA treatment, by itself, resulted in molecular weight shift as seen 
in P and VC samples. 
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Appendix F 
STAT-3 siRNA treatment in T98G cells leads to MMP-1 induciton 
 
T98G cells treated with STAT3 siRNA show a significant knockdown of STAT3 (total) 
protein levels.  In these samples, MMP-1 expression was observed to be remarkably high 
as compared to scrambled (scr) and oligofectamine (oligo) (transfection reagent) controls.  
Lower panel figure shows that the levels of phospho- and total ERK do not change 
among the three sample groups- Scrambled, Ogofectamine and STAT3 siRNA-treated 
T98G cells. 
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